

**Not intended to be a comprehensive curriculum review, but hopefully a useful collection of:**

Scoring systems

Acronyms

Definitions

Algorithms

Guidelines

Recipes

**Nick Eaddy**

**June 2018**

# CONTENTS

<b>Chapter</b>	<b>Page</b>	<b>Topic</b>
<b>1</b>	3	Airway
<b>2</b>	8	Cardiology
<b>3</b>	16	Crisis
<b>4</b>	20	Endocrine
<b>5</b>	24	Haematology
<b>6</b>	27	Intensive Care
<b>7</b>	33	Neurology
<b>8</b>	37	Obesity
<b>9</b>	39	Obstetrics
<b>10</b>	42	Orthopaedics
<b>11</b>	43	Paediatrics
<b>12</b>	47	Pain
<b>13</b>	49	Perioperative
<b>14</b>	53	Professional
<b>15</b>	61	Research and Statistics
<b>16</b>	63	Respiratory and Thoracics
<b>17</b>	66	Trauma

# 1 - AIRWAY

## Cook Modified Cormac and Lehane

		<u>Frequency</u>	<u>Difficulty</u>
<b>GD I</b>	Full View	68%	<1%
<b>GD IIa</b>	Partial Glottis	24%	4%
<b>GD IIb</b>	Posterior Glottis	6.5%	67%
<b>GD IIIa</b>	Elevated Epiglottis	1.2%	87.5%
<b>GD IIIb</b>	Depressed Epiglottis	RARE	
<b>GD IV</b>	No Epiglottis	VERY RARE	

## Laryngeal Masks

<u>LMA</u>	<u>Weight</u>	<u>Cuff Volume</u>	
<b>1</b>	<5 kg	4 mL	} Volume = 4 x Size
<b>1.5</b>	5-10 kg	6 mL	
<b>2</b>	10-20 kg	10 mL	
<b>2.5</b>	20-30 kg	15 mL	} Volume = 10 x (size-1)
<b>3</b>	30-50 kg	20 mL	
<b>4</b>	50-70 kg	30 mL	
<b>5</b>	70-100 kg	40 mL	
<b>6</b>	>100 kg	50 mL	

## Airway Tests

(Source = ANZCA Airway Document)

**SPIN** = Specific Test, + rules in = Low False +

**SNOUT** – Sensitive Test, - rules out = Low False –

	<u>Sens</u>	<u>Spec</u>
<b>Prognathe</b>	20%	95%
<b>MO</b>	35%	95%
<b>MP</b>	50%	85%
<b>TMD</b>	80%	80%
<b>Arne Score</b>	90%	90%

## Arne Score

(Source = ANZCA Airway Document)

- P** - Pathology associated with difficulty
- R** - ROM of neck
- E** - Experiences symptoms of airway pathology
- D** - Difficulty previously
- I** - Interincisor Gap
- C** - Class (Mallampati)
- T** - Thyromental Distance

## NAP4 Themes

(Source = NAP4 Summary 2011)

- F** - Failure to plan for failure
- A** - AFOI was often indicated, but not performed
- I** - Increased failure seen with cannula cricothyroidotomy
- L** - Large people are at increased risk
- E** - Emergence from anaesthesia contributes 1/3 of cases
- D** - Deaths: ICU = Trache/ no capnography, Anaesthesia = Aspiration
  
- P** - Perseverance to intubate
- L** - LMAs used inappropriately
- A** - Airway assessment was not performed, or technique not modified to suit
- N** - Neck/ Facial surgery increases risk
- S** - Strategies weren't employed, just plans

## Fremantle Score

(Source = Blue Book 2013)

Grading system for Laryngeal view on videolaryngoscopy

3 Components:

- 1 **View of Larynx in the absence of cricoid manipulation**  
Full, partial, none
- 2 **Ease of task**  
Easy, modified (bougie, cricoid), unachievable
- 3 **Device used**  
Videolaryngoscope and blade

## Murphy and Wall Scores - BMV

(Source = ANZCA Airway document)

Difficult BMV = **MOANS**

- M** - Mask seal poor due to beard
  - O** - Obesity, BMI > 26 kg/m<sup>2</sup>
  - A** - Age > 55 years
  - N** - No teeth
  - S** - Snoring
- OR ~2-3x for each factor, spec/sense ~70% if >2 factors

## Murphy and Wall Scores - LMA

(Source = ANZCA Airway document)

Difficult LMA = **RODS**

- R** - Reduced MO
  - O** - Obstruction at or below the larynx
  - D** - Disrupted Airway
  - S** - Stuff lungs/ neck
- Difficult LMA = Failure in 3 attempts to achieve
- 1 Vt = 7 mL/kg
  - 2 Leak Pressure >15cmH<sub>2</sub>O

Murphy and Wall Scores - ETT

(Source = ANZCA Airway document)

Difficult ETT = **LEMONS**

- L** - Looks difficult externally
- E** - Examination – TMD <4cm, MO <5cm
- M** - Mallampati class
- O** - Obstruction
- N** - Neck mobility

Murphy and Wall Scores - Cricothyroidotomy

(Source = ANZCA Airway document)

Difficult Cricothyroidotomy = **SHORT**

- S** - Surgery to neck
- H** - Haematoma or infection
- O** - Obesity
- R** - Radiation
- T** - Tumour

ALSO – Age <8years, Female, C-Spine fixation, deflection deformity

Hans BMV Score

(Source = ANZCA Airway document)

	<u>Technique</u>	<u>Frequency</u>
<b>Grade I</b>	Mask	77%
<b>Grade II</b>	Mask + Adjunct	21%
<b>Grade III</b>	2 Person, unstable	1.4%
<b>Grade IV</b>	Can't BMV	0.16%

Grade III+ = Difficult BMV

ANZCA Airway Overview Questions

(Source = ANZCA Airway document)

9 questions = **DIFFICULT**

- D** - Documented previous difficulty?
- I** - Impact of surgery on airway?
- F** - Facemask/ BMV difficult?
- F** - FONA difficult?
- I** - Intubation difficult?
- C** - CVS/ Resp physiology altered?
- U** - Unable to place LMA?
- L** - Landing phase – Will there be a difficult extubation?
- T** - Throw up/ Aspiration risk?

## Rheumatoid Cervical Spine

(Source = CEACCP 2006)

30% have C-Spine involvement

25% of these have unstable C-Spines

### **Atlanto-Axial Instability**

1 - Anterior = 80%

C1 moves anterior on C2

Gap between C1 anterior Arch and Peg >3-4mm

Worse on flexion

2 - Vertical = 10-20%

Superior migration of the Peg due to disruption of the C1 lateral masses

3 - Posterior = 5%

C1 moves posterior over C2

Due to destruction of the Peg

4 - Lateral/ Rotatory

Super rare

### **Subaxial Subluxation**

Common. Causes early symptoms of nerve compression

## C-Spine Extubation

(Source = Blue Book 2017)

For deciding whether to extubate after C-spine surgery, One point for each of **CSPINE**

- C** - Combined anterior and posterior approach
- S** - Surgery to  $\geq 3$  levels
- P** - Preoperative Myelopathy
- I** - In theatre for >5 hours
- N** - Neck fusion involving C2
- E** - EBL >300mL

### SCORE

**1-2** = Extubate at bend of case

**2-3** = Consider delayed extubation

## Dental Notation

(Source = ISO/ WHO)

### Permanent

Molars	Premolars	Canines	Incisors	Incisors	Canines	Premolars	Molars
18, 17, 16	15, 14	13	12, 11	21, 22	23	24, 25	26, 27, 28
48, 47, 46	45, 44	43	42, 41	31, 32	33	34, 35	36, 37, 38

### Primary

Molars	Canines	Incisors	Incisors	Canines	Molars
55, 54	53	52, 51	61, 62	63	64, 65
85, 84	83	82, 81	71, 72	73	74, 75

## Laryngotracheal Trauma


(Source = BJA/ Brisbane ASM 2017/ EMAC)

### **Major Signs**

- Dyspnea, Stridor, Orthopnea, Emphysema

### **Minor Signs**

- Swelling, Haemoptysis, Dysphonia, Dysphagia



## LMA for Laparoscopy

### **Rule of 20's**

- <20kg over IBW
- <20° Head Down
- No leak at 20 cmH<sub>2</sub>O
- <20 minutes duration

## 2 - CARDIOLOGY

### Pulmonary Hypertension Severity

(Source = LITFL)

**RVSP** = Right Ventricular Systolic Pressure

**mPAP** = Mean Pulmonary Artery Pressure

**sPAP** = Systolic Pulmonary artery pressure

**RVSP** = sPAP in the absence of PS

	<u>mPAP</u>
<b>Mild</b>	25 – 40mmHg
<b>Moderate</b>	41 – 55mmHg
<b>Severe</b>	>55mmHg

**mPAP** = (0.6x RVSP) +2 - If RVSP = 40mmHg, mPAP = 25mmHg

RVSP measured from TR Jet + CVP

### Mitral Stenosis Severity

Normal MVA >4cm<sup>2</sup>

In MS MVA decreases by 0.2cm<sup>2</sup>/year

Gradations for MS and AS severity by area have the same cutoffs

Gradations for MS severity by MG = those for AS/4

	<u>MVA</u>	<u>MG</u>	<u>Pt<sub>1/2</sub></u>
<b>Mild</b>	1.6 – 2cm <sup>2</sup>	<5mmHg	<140ms
<b>Moderate</b>	1 – 1.6cm <sup>2</sup>	6 – 10mmHg	140 – 220ms
<b>Severe</b>	<1cm <sup>2</sup>	>10mmHg	>220ms

### Mitral Regurgitation Severity

Global gestalt, Vena Contracta, Coanda effect

	<u>Fraction</u>	<u>Volume</u>	<u>Orifice</u>
<b>Mild</b>	<30%	<30mL	<0.2 cm <sup>2</sup>
<b>Moderate</b>	30-50%	30-60mL	0.2 – 0.4 cm <sup>2</sup>
<b>Severe</b>	>50%	>60mL	>0.4 cm <sup>2</sup>

### Continuity Equation

Used to determine AVA

$$SV_{AV} = SV_{LVOT}$$

$$AVA \times VTI_{AV} = CSA_{LVOT} \times VTI_{LVOT}$$

$$\therefore AVA = \frac{CSA_{LVOT} \times VTI_{LVOT}}{VTI_{AV}}$$



Aortic Stenosis Severity

	AVA	MG	Vmax	Indexed AVA
<b>Mild</b>	>1.5 cm <sup>2</sup>	<20 mmHg	2.6 – 2.9 ms <sup>-1</sup>	>0.85 cm <sup>2</sup> /m <sup>2</sup>
<b>Moderate</b>	1 – 1.5 cm <sup>2</sup>	20 - 40 mmHg	3 – 4 ms <sup>-1</sup>	0.6 - 0.85 cm <sup>2</sup> /m <sup>2</sup>
<b>Severe</b>	<1 cm <sup>2</sup>	>40 mmHg	>4 ms <sup>-1</sup>	<0.6 cm <sup>2</sup> /m <sup>2</sup>
$\Delta$ / Year	0.1 cm <sup>2</sup> / year	10 mmHg/ year	0.3 ms <sup>-1</sup> / year	

Other Measures:

- DI = Dimensionless Index <0.25 = Severe
- AVA via planimetry

Aortic Stenosis Mortality

<b>Angina</b>	50% @ 5 years
<b>Syncope</b>	50% @ 3 years
<b>Failure</b>	50% @ 2 years

Diastolic Dysfunction

<u>NORMAL</u>	<u>ABNORMAL</u>
E/A = 1-1.5	
e' > 12cms <sup>-1</sup>	e' < 8cms <sup>-1</sup>
E/e' < 8	E/e' > 15

		E/A	e'	E/e'	DT
<b>GRADE 1</b>	<b>Impaired Relaxation</b>	<1	<8cms <sup>-1</sup>	<8	>240ms
<b>GRADE 1a</b>	<b>Abnormal Filling</b>	<1	<8cms <sup>-1</sup>	>15	160-240ms
<b>GRADE 2</b>	<b>Pseudonormal</b>	1 – 1.5	<8cms <sup>-1</sup>	>15	160-240ms
<b>GRADE 3/4</b>	<b>Restrictive</b>	>2	<8cms <sup>-1</sup>	>15	<160ms

GRADE 3 = Reversible with Valsava

GRADE 4 = Irreversible


OTHER MEASURES

- D/S = Pulmonary Blood flow
- A<sub>R</sub> = Diastolic Flow Reversal
- LA area > 20cm<sup>2</sup>

Murmurs


**Mitral Stenosis**

Diastolic murmur




**Mitral Regurgitation**

Pansystolic murmur




**Aortic Stenosis**

Crescendo-Decrescendo



**Aortic Regurgitation**

Decrescendo diastolic S1



Austin Flint due to Functional MS

## Fontan Circulation

- STAGE 1**      Norwood Procedure = Palliative Systemo-pulmonary Shunt  
Blalock-Thames-Taussig Shunt, Sano Shunt, Hybrid Procedure
- STAGE 2**      Glenn Bidirectional Shunt = Superior cavo-pulmonary shunt
- STAGE 3**      Completion Fontan = Total Cavo=Pulmonary Shunt

## Lee's Revised Cardiac Risk Index

Published 1999 expanding on Goldman's Cardiac Risk Index

### **6 Factors**

- Ischaemic Heart Disease
- Congestive Heart Failure
- Cerebrovascular Disease
- Diabetes
- Chronic Kidney Disease
- Suprainguinal Vascular/ Thoracic/ Intraperitoneal Surgery

Score:	Risk of Cardiac Event (Cardiac Death, non-fatal MI, non-fatal arrest)
<b>0</b>	0.4%
<b>1</b>	0.9%
<b>2</b>	6.6%
<b>≥3</b>	11.1%

## NSQIP

American College of Surgeons National Surgical Quality Improvement Programme

Algorithmic risk predictor which utilizes:

18 patient parameters

Procedure being performed

### **PARAMETERS:**

- Age
- Gender
- Functional state
- Emergency
- ASA
- Steroids
- Ascites
- Sepsis
- Ventilator
- Metastases
- Diabetes
- CHF
- Dyspnea
- Smoker
- Severe COPD
- Dialysis
- AKI
- BMI

+ Procedure

### **OUTPUTS:**

- Serious Complication
- Surgical Infection
- Readmission
- Any complication
- UTI
- Return to OT
- Pneumonia
- VTE
- Death
- Renal Failure
- MACE
- DC to Resthome

EHRA Score


(Source = EHRA)

European Heart Rhythm Association score of AF related symptoms

- 1 - No Symptoms
- 2 - Mild, daily activities unaffected
- 3 - Severe, daily activities affected
- 4 - Disabling, daily activities discontinued

Coronary Artery Disease Assessment

(Source = 2014 ACC/AHA)



NSTEMI Types

- TYPE I** Plaque rupture
- TYPE II** Supply-demand mismatch
- TYPE III** Sudden Cardiac Death
- TYPE IV** Post PCI
- TYPE V** Post CABG

### NYHA Dyspnea

<b>NYHA I</b>	No Limitation of normal activities
<b>NYHA II</b>	Slight limitation of normal activities, comfortable at rest
<b>NYHA III</b>	Marked limitation of normal activities, comfortable at rest
<b>NYHA IV</b>	Severe limitation, dyspneic at rest

### CCS Angina

<b>CCS I</b>	No Limitation of normal activities
<b>CCS II</b>	Slight limitation of normal activities, comfortable at rest
<b>CCS III</b>	Marked limitation of normal activities, comfortable at rest
<b>CCS IV</b>	Severe limitation, angina at rest

### CHA<sub>2</sub>DS<sub>2</sub>-VASc Score

Recommended by European Society of Cardiologists (2012) and ACC/AHA (2014)

HAS-BLED = Bleeding Risk Score

#### Points:

1	<b>C</b>	– CHF or LV Dysfunction
1	<b>H</b>	– Hypertension
2	<b>A</b>	– Age >75 years
1	<b>D</b>	– Diabetes
2	<b>S</b>	– Stroke/ TIA
1	<b>V</b>	– Vascular Disease
1	<b>A</b>	– Age 65-74 years
1	<b>Sc</b>	– Sexual Category = Female

#### Score:

<b>0</b>	0.2%
<b>1</b>	1.3%
<b>2</b>	2.2%
<b>3</b>	3.2%
<b>4</b>	4.0%
<b>5</b>	6.7%
<b>6</b>	9.8%
<b>7</b>	9.6%
<b>8</b>	12.5%
<b>9</b>	15.2%

#### Score:

<b>0</b>	= No anticoagulation
<b>1</b>	= Anticoagulate if male
<b>&gt;2</b>	= Anticoagulate

INR must be therapeutic >70% of time to decrease risk

### CHADS<sub>2</sub> Score

If previous CVA then automatically risk >8.5%/ year for further CVA

#### Points:

1	<b>C</b>	– CHF
1	<b>H</b>	– Hypertension
1	<b>A</b>	– Age >75 years
1	<b>D</b>	– Diabetes
2	<b>S</b>	– Stroke/ CVA

#### Score:                      Stroke Risk/ year:

<b>0</b>	2%
<b>1</b>	3%
<b>2</b>	4%
<b>3</b>	6%
<b>4</b>	8.5%
<b>5</b>	12.5%
<b>6</b>	18%

### Perioperative CVA Risk

(Source = ANZCA Blue Book 2017)

**High Risk** = Bridge

**Moderate Risk** = Risk/ Benefit. Low threshold to bridge

**Low Risk** = No Bridging

<b>Risk</b>	<b>CVA %/ Year</b>	<b>Valves</b>	<b>AF</b>
<b>High</b>	>10%/ year	All MVRs Mechanical AVR CVA in last 6 months	CHADS 5-6 CVA in last 3 months
<b>Moderate</b>	4-10%/ year	Bileaflet AVR + Chads $\geq$ 1	CHADS 3-4
<b>Low</b>	<4%/ year	Bileaflet AVR	Chads $\leq$ 2

### Post-PCI Thrombotic Risk

(Source = ACC 2017)

Consider: Indication, risk of continuing, risk of discontinuing

	<u>30 day risk of MI/CVS death</u>		
	<u>1%</u>	<u>1-5%</u>	<u>&gt;5%</u>
<b>Balloon Angioplasty</b>	>4 weeks	2-4 weeks	<2 weeks
<b>BMS</b>	>6 months	1-6 months	<1 month
<b>DES</b>	>12 months	6-12 months	<6 months

## NSPE/ BPEG Pacemaker/ ICD codes

Pacemaker:

### **Letter 1 = Pacing Chamber**

O = None      V = Ventricle  
A = Atria      D = Dual

### **Letter 2 = Sensing Chamber**

O = None      V = Ventricle  
A = Atria      D = Dual

### **Letter 3 = Sensing Response**

O = None      I = Inhibited  
T = Triggered    D = Dual T + I

### **Letter 4 = Programmability**

O = None      R = Rate modulation

### **Letter 5 = Multisite pacing**

O = None      V = Ventricle  
A = Atria      D = Dual

ICD:

### **Letter 1 = Shock Chamber**

O = None      V = Ventricle  
A = Atria      D = Dual

### **Letter 3 = Tachycardia Detection**

E = ECG      H = Haemodynamic

### **Letter 2 = Antitachycardia Pacing Chamber**

O = None      V = Ventricle  
A = Atria      D = Dual

### **Letter 4 = Antibradycardia Pacing Chamber**

O = None      V = Ventricle  
A = Atria      D = Dual

## Stages of Hypertension

<u>Stage</u>	<u>sBP</u>	<u>dBp</u>
<b>1</b>	140-159	90-99
<b>2</b>	160-179	100-109
<b>3</b>	180-209	110-119
<b>4</b>	≥210	≥120

## CRT-D Indications

(Source = European Society of Cardiology)

Most benefit for Females, non-ischaemic cardiomyopathy

- C** - Conduction Abnormality
  - LBBB – QRS >120ms
  - Non-LBB – QRS >150ms
- R** - Reduced LVEF ≤35%
- T** - Treatment optimized medically
- D** - Dyspnea
  - AF – NYHA III-IV
  - SR – NYHA II-IV

MACE Risk in Heart Failure

(Source = ACC/AHA)

**MACE** = Major adverse cardiac event

30 day MACE in Elective Vascular Surgery

<b>Symptomatic Heart Failure</b>		50%
<b>Asymptomatic</b>	- LV Systolic Dysfunction	25%
	- LV Diastolic Dysfunction	20%
<b>Normal LV Function</b>		10%

### 3 - CRISIS

#### Drugs down an ETT

Generally not recommended though

- N** - Naloxone
- A** - Adrenaline
- V** - Vasopressin
- A** - Atropine
- L** - Lignocaine

#### Causes of Cardiac Arrest

- |                               |                                 |
|-------------------------------|---------------------------------|
| <b>H</b> - Hypoxia            | <b>T</b> - Tension Pneumothorax |
| <b>H</b> - Hypovolaemia       | <b>T</b> - Tamponade            |
| <b>H</b> - Hypothermia        | <b>T</b> - Toxins               |
| <b>H</b> - Hyo/ Hyperkalaemia | <b>T</b> - Thrombus             |

#### Adult Anaphylaxis

>12 years of age

(Source = ANZCA)

- DR** - Danger and Response  
Stop procedure, remove trigger
- S** - Send for help and form a team  
Anaphylaxis Box  
Leader and a Reader
- AB** - Airway/ Breathing  
FiO2 = 100%, ETT early
- C** - Circulation  
Raise legs  
Volume = 2L crystalloid
- D** - Drugs  
ADRENALINE

#### **IM ADRENALINE**

If no IV access/ no haemodynamic monitoring  
ADRENALINE 1:1000, 0.5mL = 0.5mg  
Lateral Thigh

#### **IV ADRENALINE**

ADRENALINE 1:10,000, 1mg/10ml, 100mcg/mL  
GD II = 0.2mL = 20mcg  
GD III = 1-2mL = 100-200mcg  
GD IV = ACLS 1mg

#### **ADRENALINE INFUSION**

After 3x Adrenaline boluses  
ADRENALINE 3mg/ 50mL  
3mL/ hr – 40mL/ hr = 3-40mcg/ min

#### **ONGOING HYPOTENSION**

NORADRENALINE 3-40mcg/ min  
VASIPRESSON 1-2 units, then 2units/ hr  
GLUCAGON 1-2mg Q5 min

#### **ONGOING BRONCHOSPASM**

SALBUTAMOL 12 puffs/ 100-200mcg IV  
MAGNESIUM 2g



## EZ-IO

(Source – Arch Pathol Lab Med 2010)

### Contraindications

- Target bone fracture
- Infection
- Orthopaedic prosthesis
- Osteogenesis imperfecta

### 15G needle

	<u>Length:</u>	<u>Weight:</u>
<b>Red</b>	15 mm	3-39 kg
<b>Blue</b>	25 mm	≥3 kg
<b>Yellow</b>	45 mm	≥40 kg

### Good IV/IO correlation:

- RBCs
- Cl<sup>-</sup>
- Urea
- Albumin
- BGL
- Hb
- Cr

### Poor IV/IO correlation:

- WCC
- PLT
- CO<sub>2</sub>
- Na<sup>+</sup>
- K<sup>+</sup>
- Ca<sup>2+</sup>

## Crisis Priorities

### **Immediate:**

- Recognise and declare
- Get help
- Temporarily resuscitate
- Mobilise a team
- Assess and diagnose
- Manage

### **Later:**

- Ongoing management
- Referrals/ Disposition
- Document
- M&M
- Debrief/ second victims/ self care
- Open disclosure

## MH Manifestations

(Source = MHANZ)

### **Early:**

- Masseter spasm
- Ventricular ectopics
- Increased ETCO<sub>2</sub>
- Tachycardia

### **Developing:**

- T increased 0.5°C/ 15min
- Sweating
- Hyperkalaemia
- CVS instability
- Respiratory acidosis

### **Late:**

- Myoglobinuria
- Coagulopathy
- Renal failure
- Raised CK

## MH Team Members

(Source = MHANZ)

### **Need 10 people**

- Leader
- Anaesthetists 1 = Resuscitation
- Anaesthetist 2 = Lines
- Nurses – Cooling
- 2x Technicians – Lines, ABG, cooling
- 3x Dantrolene mixers
- Surgeon – IDC, cooling
- Theatre coordinator - Logistics

## Trigger-Free Anaesthetics

(Sources = MHANZ, Blue Book 2017, EMHG)

### **Give to patients at risk of MH**

- Confirmed/ equivocal MH testing – IVCT + DNA
- RyR Myopathies – King Denborough, Central Core Disease
- Recurrent, unexplained Rhabdomyolysis
- Pregnant woman with MH partner
- Family History
  - + IVCT in a relative
  - - DNA in a relative (but still at risk)
  - - Untested relative with an MH reaction

## IVCT = In Vitro Contracture Testing

(Sources = Blue Book 2017, EMHG)

Halothane 2% = 0.44 mmol/L

Requires a 4x3x1 cm piece of Quads Muscle

Must be >30 kg/ >10 years of age

	<u>Caffeine:</u>	<u>Halothane:</u>	
<b>MHShc</b>	<2 mmol/L	<2%	- Halothane/ Caffeine sensitive
<b>MHSh</b>	>3 mmol/L	<2%	- Halothane Sensitive
<b>MHSc</b>	<2 mmol/L	>2%	- Caffeine Sensitive
<b>MHN</b>	>3 mmol/L	>2%	- Normal

## Needlestick Transmission Rates

(Source = BMJ)

	<u>Risk:</u>	
<b>Hep B</b>	1/3 – 33%	When HbE +
<b>Hep C</b>	1/30 – 3%	
<b>HIV</b>	1/300 – 0.3%	

## Venous Air Embolism

V = 5 mL/kg = Cardiac arrest

<u>Monitoring:</u>	<u>Sensitivity:</u>
<b>Precordial Stethoscope</b>	V = 1.5 mL/kg
<b>EtCO<sub>2</sub></b>	V = 0.5 mL/kg
<b>Precordial Doppler</b>	V = 0.05 mL/kg
<b>TOE</b>	V = 0.02 mL/kg

## Positioning

- Trendelenburg = Keep LV bubble away from the coronaries
- Left lateral = Traps bubble in RV

## Pseudocholinesterase Deficiency

<u>Genotype:</u>	<u>Frequency:</u>	<u>Phenotype:</u>
<b>Homozygous Normal</b> = E <sub>U</sub> /E <sub>U</sub>	96%	Normal
<b>Heterozygotes</b> = E <sub>U</sub> /E <sub>A</sub> , E <sub>S</sub> , E <sub>F</sub>	4%	Block for 10 minutes
<b>Homozygous Abnormal</b> = E <sub>S</sub> /E <sub>S</sub> , E <sub>A</sub> /E <sub>A</sub> etc	<1%	Block for 4-8 hours

	<u>Dibucaine Number:</u>	<u>Fluoride Number:</u>
<b>NORMAL</b>	80 = 80% enzyme suppression	60 = 60% enzyme suppression
<b>ABNORMAL</b>	20 = 20% enzyme suppression	36 = 36% enzyme suppression

## Infusions

<u>ADRENALINE</u>	Anaphlaxis
Adult	3mg /50mL @ 3-40 mL/ hr
Paediatrics	1mg /50mL @ 0.3-6 mL/kg/hr

ISOPRENALINE Life-threatening bradycardia  
1 mL 1:5000 = 0.2mg in 50 mL = 4 mcg/mL  
Infuse at 1.25 mL/hr

<u>VASOPRESSIN</u>	
Adult	Bolus = 1-2 units, Infuse @ 1-2 units/hr
Paediatrics	1 unit/kg/50mL. Bolus = 2mL, Infuse @ 1-3 mL/hr

<u>NORADRENALINE</u>	
Adult	4 mg/50mL @ 0-40 mL/hr
Paediatric	0.15 mg/kg/50mL @ 0-40 mL/hr

## RV Failure

- Reverse precipitant
- Maintain SVR – Metaraminol, Vasopressin
- Maintain CO – Rhythm, Contractility
- Lower PVR
  - Vasopressor – Vasopressin has less effect on PVR
  - Iloprost – Need USS nebulizer, 2.5-5 mg or 2.5 mcg/kg
  - Milrinone – 2 mg (50mcg/kg) nebulized
  - Peep, FiO<sub>2</sub>, Increase P<sub>a</sub>O<sub>2</sub>, lower P<sub>a</sub>CO<sub>2</sub>, Temperature, pH
  - Analgesia – Morphine/ Ketamine

## 4 - ENDOCRINE

### Steroid Effects

- C** - Cataracts
- U** - Ulcers
- S** - Striae/ Skin thinning
- H** - Hirsutism/ Hypertension
- I** - Immunosuppression/ Infections
- N** - Necrosis of femoral head
- G** - Glucose
- O** - Osteoporosis/ Obesity
- I** - Impaired Healing
- D** - Depression/ Mood changes

### Phaemochromocytome Optimisation:

#### **Goals:**

- Reduce mortality 50-6%
- Reduce cardiac dysfunction
- Reduce BP/SVR
- Volume expansion
- Reduce chance of hypertensive crisis
- Adrenergic resensitisation

#### **Criteria:**

- BP <160/90
- No STE on ECG
- Normal BGLs
- Orthostatic Hypotension
- Normal HCT
- Nasal congestion

### HPA Axis Suppression

(Source = Margo)

<u>Suppression:</u>	<u>Steroid Exposure:</u>	<u>Management:</u>
<b>Nil</b>	<ul style="list-style-type: none"><li>- Prednisone &lt;5 mg/day</li><li>- &lt;3 weeks exposure</li><li>- Every other day regimens</li></ul>	<ul style="list-style-type: none"><li>- Take usual dose</li><li>- No testing</li><li>- No supplementation</li></ul>
<b>Maybe</b>	<ul style="list-style-type: none"><li>- Prednisone 5-20 mg/day</li><li>- Inhaled steroid</li><li>- Topical steroid</li></ul>	<p>Either:</p> <ul style="list-style-type: none"><li>- Test = Short Synacthen Test</li><li>- Empiric supplementation</li></ul>
<b>Definite</b>	<ul style="list-style-type: none"><li>- Prednisone &gt;20 mg/day</li><li>- &gt;3 weeks exposure</li><li>- Cushingoid</li></ul>	<ul style="list-style-type: none"><li>- Supplement steroid</li></ul>

<u>Surgery:</u>	<u>Preoperative:</u>	<u>Intraoperative:</u>	<u>Postoperative:</u>
<b>Minor</b> - Hernia - Colonoscopy - Plastics	Usual	Nil	Usual
<b>Moderate</b> - Cholecystectomy - Arthroplasty	Usual	Hydrocort 50mg	Hydrocort 25mg Q8hr for 24hr then usual
<b>Major</b> - Whipples - Liver	Usual	Hydrocort 100mg	Hydrocort 50mg Q8hr for 24hr then ½ taper to usual

	<u>Potency:</u>	<u>Dose:</u>
<b>Hydrocortisone</b>	1	100 mg
<b>Prednisone</b>	5	20 mg
<b>Dexamethasone</b>	25	4 mg

# 5 - EQUIPMENT

## Electrical Equipment

<u>Class:</u>	<u>Features:</u>
<b>Class I</b>	Metal casing Earth (3 <sup>rd</sup> pin) Fuse to break circuit
<b>Class II</b>	Double insulation No Earth
<b>Class III</b>	Isolating transformer +/- LIM Low Voltage <24V AC, <50V DC <u>or</u> Internal Power Supply

## Electrical Equipment in Contact with Patients

<u>Class:</u>	<u>Features:</u>
<b>Class B</b>	Class I, II or III Leak <100 $\mu$ A External use only
<b>Class BF</b>	Class B with a floating circuit
<b>Class CF</b>	Very low leak currents Safe to connect to heart

**Body Protected Area** = Protection from macroshock = RCDs, LIMs

**Cardiac Protected Area** = Protection from microshock = RCDs, LIMs, Equipotential Earthing

## Power Failure

**White Plug** = Mains electrical, no backup

**Red Plug** = Generator backup, 15-30s delay

**Blue Plug** = UPS

**UPS** = Uninterrupted Power Supply

**Emergency Lighting** = Low light, battery powered, will last for 90 minutes

**Operating Lighting** = Battery powered, will last for 90 minutes

**Anaesthetic Machine** = Inbuilt UPS, will last for 90 minutes

**Pumps** = Battery, time dependent on charge

Appraisal of Equipment

(source = ANZCA Blue Book 2015)

**APPRAISE**

<b>A</b>	<b>- Affordability</b>	Capital, maintenance, disposables
<b>P</b>	<b>- Portability</b>	Size, power supply
<b>P</b>	<b>- Purpose built</b>	Suitable for use
<b>R</b>	<b>- Reliability</b>	Works when needed
<b>A</b>	<b>- Acceptability</b>	By users
<b>I</b>	<b>- Integration</b>	Works with other equipment
<b>S</b>	<b>- Sturdy</b>	Durability
<b>E</b>	<b>- Environmental Impact</b>	Ecological cost

# 5 - HAEMATOLOGY

## Transfusion Infections

(Source = Transfusion.com.au)

Agent:	Window Period:	Residual Risk/ Unit
<b>HIV</b>	6 days	<1:1000,000
<b>HCV</b>	3 days	<1:1000,000
<b>HBV</b>	15 days	1:700,000
<b>Malaria</b>	10 days	<1:1000,000

## Herbs

**Echinacea** = Hepatotoxic

**Garlic** = Reduces TXA<sub>2</sub>, inhibits platelet aggregation

**Ginger** = Reduces TXA<sub>2</sub>, inhibits platelet aggregation

**Ginkgo** = Potent platelet inhibitor

**Ginseng** = Platelet inhibitor

**Kava** = Hepatotoxic

**St. Johns Wart** = Reduces 5HT<sub>3</sub>/NA/DA reuptake, CYP3A4/2C9 inducer (reduces Warfarin/ increases Clopidogrel effect)

## Heparin Induced Thrombocytopenia

	Type I	Type II
<b>Timing</b>	<4 days	>4 days
<b>Thrombocytopenia</b>	Mild	>50%
<b>Thrombosis</b>	No	Yes
<b>Life Threatening</b>	No	Yes
<b>Mechanism</b>		IgG anti-Heparin/PF4 Complex

## MABL

**MABL** = Maximal Acceptable Blood Loss. Can be used as a trigger for transfusion

$$\text{MABL} = \text{EBV} \times \frac{\text{HCT}_{\text{Start}} - \text{HCT}_{\text{Target}}}{\text{HCT}_{\text{Target}}}$$

$$\text{HCT}_{\text{Target}} = 25-30\%$$

$$\text{EBV} = 70 \text{ mL/kg in children}$$

$$= 50-60 \text{ mL/kg in adults}$$

$$\text{MABL} = 2(\text{age}+4) \times 0.4 \times 70$$

$$= 0.8(\text{age}+4) \times 70$$

$$= 50(\text{age}+4)$$



## Blood Components

(Source = ADHB, Australian Red Cross)

<u>Component</u>	<u>Composition</u>	<u>Volume</u>	<u>Dose</u>	<u>Storage</u>
<b>RBC</b>	Hb 50 g/unit HCT = 0.6 Leuc = $0.3 \times 10^6$ /unit	<b>Adult</b> = 2-300 mL <b>Paed</b> = 50-100 mL	Increase Hb $\sim 10$ g/L <b>Adult</b> = 1 unit <b>Paed</b> = 4 mL/kg	42 days at 2-6°C
<b>Platelets</b>	PLT $280 \times 10^9$ /unit Leuc = $0.2 \times 10^6$ /unit	<b>Adult</b> = 2-300 mL <b>Paed</b> = 50-100 mL	Increase PLT $20-40 \times 10^9$ /L <b>Adult</b> = 1 unit <b>Paed</b> = 10 mL/kg	5 days at 20-24°C on an agitator
<b>Cryo</b>	Fibrinogen = 1.2g - Factor VIII - Factor XIII vWF Fibrinectin	100mL	Increase Fib by 1.0 g/L <b>Adult</b> = 1 unit/30 kg <b>Paed</b> = 5 mL/kg	12 months at -30°C 4 hrs at 20-24°C
<b>FFP</b>	All Coag Factors Labile Factors - Factor V - Factor VIII Low Fib = 1.6 g/L	<b>Adult</b> = 2-300 mL <b>Paed</b> = 50-100 mL	Increase Factors by 30% <b>Adult</b> = 15 mL/kg <b>Paed</b> = 10-15 mL/kg	12 months at -30°C 24 hrs at 2-6°C Extended Life = 5 days at 2- 6°C

## Transfusion Time Limits

(Source = NZBB 2016)

<u>Component:</u>	<u>Commence:</u>	<u>Complete:</u>	<u>Return:</u>	<u>Re-Issue:</u>
<b>RBC</b>	ASAP	<4 hours	<30 min	<30 days
<b>Platelets</b>	ASAP	<1 hour	<1 hours	<5 days
<b>Cryo</b>	ASAP	<4 hours	<30 min	4 hours @ room temp
<b>FFP</b>	ASAP	<4 hours	<30 min	24 hours @ 2-6°C
<b>EL FFP</b> = Extended Life FFP				EL = 7 days @ 2-6°C but with loss of labile factors

## Indications for Cell Salvage

- Anticipated blood loss >750 mL/ 20% volume
- Blood loss sufficient to cause anaemia
- Rare blood groups/ JW/ Antibodies
- Surgery that >10% of people require transfusion

## Massive Transfusion

### Indication:

- Haemorrhage >150 mL/min
- Shock and coagulopathy

### Definition:

- >10 units/24 hours
- >5 units/4 hours

### Principles:


- 1:1 of RBC:FFP
- TXA
- Check Coags/ Platelets/ Hb/  $Ca^{2+}$  Q30mins

### Thresholds:

- Maintain  $Ca^{2+}$  >1.0 mmol/L
- 4 FFP if INR >1.5 or APTT > 40
- 3 Cryo if Fib <2.0 g/L
- 1 Platelets if Plt <75 g/L

### Goals:

- T >36°C
- pH >7.2
- $Ca^{2+}$  >1.0 mmol/L
- Hb >70 g/L
- PLT >75 g/L
- Fib >2.0 g/L
- INR <1.5
- APTT <40



## 6 - INTENSIVE CARE

### Organ Ischaemia Times

(Sources = ANZICS, nedonation.org)

	<u>Warm</u>	<u>Cold</u>
<b>Heart</b>	30 mins	4 hours
<b>Lungs</b>	90 mins	4-6 hours
<b>Liver</b>	30 mins	6-10 hours
<b>Intestines</b>		6-12 hours
<b>Pancreas</b>	60 mins	12-18 hours
<b>Kidneys</b>	60 mins	24 hours

### DBD – Donation after Brain Death

#### **Determination requires:**

- Unresponsive coma - Apnea
- Absence of brainstem reflexes

#### **Prerequisites:**

- Evidence of intracranial pathology - No sedation
- Normothermia T >35°C - Intact neuromuscular function
- Normotension MAP >60mmHg - No metabolic cause for coma

#### **Observation period:**

- GCS 3 for 24 hours

#### **Formal examination:**

- 2 Doctors, 2 separate tests
- Apnea – Preoxygenate and observe
- Absent Brainstem Reflexes Bilaterally
  - Pupils – CN II/III - Gag – CN IX/X
  - Cornea – CN V/VII - Vestibulocochlear – CN III, IV, VI, VIII

#### **Donor Management:**

- Overall aims
  - Optimize organ perfusion - Protect organ function
- Temperature
  - Warm/ cool to 36.5-38 °C
- Cardiovascular
  - sBP >100mmHg, MAP>70 mmHg, HR 60-120, Hb >100 g/L
- Respiratory
  - Lung protective ventilation, FiO<sub>2</sub> <0.5, PEEP 5 cmH<sub>2</sub>O, P<sub>a</sub>O<sub>2</sub> >100 mmHg
- Renal/ fluids
  - Manage DI, UO 0.5-3 mL/kg/hr
- Musculoskeletal
  - Relaxation because of spinal reflexes

## DCD – Donation after Cardiac Death

### - **Determination requires:**

- Immobility
- Apnea
- No pulse for 2 minutes
- No skin perfusion

## Cardiac Death Categories

<b>CATEGORY 1</b>	Dead on arrival
<b>CATEGORY 2</b>	Failed CPR
<b>CATEGORY 3</b>	Withdrawal in ICU
<b>CATEGORY 4</b>	Cardiac arrest post Brain Death certification

## Approach to patients with transplanted Organs

(Source = Margo)

### **Consider:**

- Indication for transplant
- Function of transplant
- Evidence of rejection
- Consequences of immunosuppression
- Physiological/ pharmacological implications of allograft denervation

## Hyponatraemia Correction

(Source = BMJ)

Either use 3% Saline or 23.4% Saline

### **3% Saline**

$$[\text{Na}^+] = 500 \text{ mmol/L}$$
$$= 0.5 \text{ mmol/L}$$

$$\therefore \text{volume to increase } [\text{Na}^+]_{\text{Plasma}} \text{ by 1 mmol/L} = (2 \times \text{TBW}) \text{ mL}$$
$$= 1 \text{ mL/kg}$$

### **23.4% Saline**

$$[\text{Na}^+] = 4000 \text{ mmol/L}$$
$$= 4 \text{ mmol/L}$$

$$\therefore \text{volume to increase } [\text{Na}^+]_{\text{Plasma}} \text{ by 1 mmol/L} = (\text{TBW}/4) \text{ mL}$$

## Hypokalaemia Correction

$$\text{K}^+_{\text{Deficit}} = (\text{K}^+_{\text{Target}} - \text{K}^+_{\text{Measured}}) \times \text{Wt}(\text{kg}) \times 0.4$$

$$\text{Total Replacement} = \text{K}^+_{\text{Deficit}} + \text{K}^+_{\text{Daily Requirement}}$$

$$\text{K}^+_{\text{Daily Requirement}} = 1 \text{ mmol/kg}$$


$$\text{K}^+_{\text{Deficit}} = 100 \text{ mmol for every } 0.3 \text{ mmol/L fall in } \text{K}^+_{\text{Plasma}}$$

Berlin Definition


2012 consensus definition for ARDS

<b>TIMING</b>	<1 week from a clinical insult
<b>IMAGING</b>	Bilateral lung opacities
<b>OEDEMA</b>	No due to cardiac causes or fluid overload
<b>OXYGENATION</b>	PF Ratios with PEEP
	- Mild PF 200-300
	- Moderate PF 100-200
	- Severe PF <100

VV-ECMO Circuit



Bypass Circuit




Sepsis III

(Source = JAMA 2016)

**Sepsis** Life threatening organ dysfunction caused by a dysregulated immune system in response to infection

**Septic Shock** Sepsis in which the underlying circulatory, cellular and metabolic abnormalities are associated with a greater risk of death



**SOFA** Sequential Organ Function Assessment Score

- CNS – GCS
- Liver – Bilirubin
- CVS – MAP + Vasopressor
- Renal – Creatinine/ Urine Output
- Resp – P/F Ratio
- Haem – Platelets

**qSOFA** Quick SOFA Score

Score  $\geq 2$  = Increased mortality, increased ICU stay

- Low BP – sBP  $\leq 100$  mmHg
- High RR – RR  $\geq 22$  /min
- Altered mentation – GCS  $< 15$

ICU Sieve

- |                               |                        |
|-------------------------------|------------------------|
| <b>F</b> - Feeding            | <b>B</b> - Bowels      |
| <b>A</b> - Analgesia          | <b>L</b> - Lines       |
| <b>S</b> - Sedation           | <b>A</b> - Antibiotics |
| <b>T</b> - Thromboprophylaxis | <b>M</b> - Medications |
| <b>H</b> - Head up            | <b>E</b> - Equipment   |
| <b>U</b> - Ulcer prophylaxis  |                        |
| <b>G</b> - Glycaemic control  |                        |

### Surgical Sieve

<b>V</b>	- Vascular	<b>C</b>	- Congenital
<b>I</b>	- Inflammatory	<b>D</b>	- Degenerative
<b>T</b>	- Traumatic	<b>E</b>	- Endocrine
<b>A</b>	- Autoimmune	<b>F</b>	- Functional
<b>M</b>	- Metabolic		
<b>I</b>	- Iatrogenic/ idiopathic		
<b>N</b>	- Neoplastic		

### Lung Protective Ventilation

(Source = Blue Book)

\* = Poor Evidence

<b>V<sub>T</sub></b>	- 6-8 mL/kg, ARDSNET		
<b>PEEP</b>	- 5-20 cmH <sub>2</sub> O, titrated to:		
	- Oxygenation	- Nitrogen washout volumes	
	- Lung USS	- P-V lower inflection point	
<b>P<sub>plateau</sub></b>	- <30 cmH <sub>2</sub> O		
<b>P<sub>a</sub>CO<sub>2</sub>*</b>	- Permissive hypercapnia, <8 kPa		
<b>FiO<sub>2</sub>*</b>	- As low as possible, Sats >90%		
<b>Proneing</b>	- PROSEVA, multicenter RCT showed reduced mortality if >16 hours/day		
<b>Recruitment*</b>	- Recruitment manouevres		
<b>Fluids</b>	- Limit IV fluids		

### Proneing in ICU

(Source = PROSEVA, NEJM 2013)

PROSEVA NEJM 2013, multicenter RCT n=500. Prone 16 hours/day, 28 day mortality reduced from 32% to 16%

#### Benefits:

- Increased lung volume
- Reduced P<sub>AW</sub> and PEEP
- Reduced over-inflation of aerated lung
- PROSEVA – Mortality benefit

#### Risks:

- Feeds intolerance
- ETT/ Trache dislodgement
- Difficult

### RIFLE Criteria

(Source = LITFL)

		<u>Creatinine</u>	<u>Urine Output</u>
<b>R</b>	- Risk	1.5x	<0.5 mL/kg for 6 hours
<b>I</b>	- Injury	2x	<0.5 mL/kg for 12 hours
<b>F</b>	- Failure	3x	<0.3 mL/kg for 24 hours or Anuria for 12 hours
<b>L</b>	- Loss	Complete loss of renal function for >4 weeks	
<b>E</b>	- ESRD	End stage renal disease	

## Approach to Transports

(Source = ANZCA)

- C** - Communicate clearly with both the referring centre and the transport agency
- H** - Have equipment/ drugs well in excess of requirements
- O** - Organise your team – Experiences medical practitioner + qualified team
- P** - Plan the transport – Vehicle, distance, location, weather
- P** - Predict physiological impact of transport – T, P, FiO<sub>2</sub>
- E** - Establish responsibility via clear handovers
- R** - Rapidly evaluate and optimize ABCDE
- E** - Establish monitoring/ infusions. Rationally defer interventions
- D** - Document everything



# 7 - NEUROLOGY

## SAH Grading

**WFNS** = World Federation of neurosurgeons, clinical grading

**Fisher** = Radiological grading

Grade	WFNS	Fisher
I	GCS 15, no motor deficit	No blood on CT
II	GCS 13-14, no motor deficit	<1 mm blood on CT
III	GCS 13-14, motor deficit	Localised clots/ >1 mm blood on CT
IV	GCS 7-12	Intracerebral/ intraventricular blood
V	GCS $\leq$ 6, moribund	

## Principles of Neuroanaesthesia

(Source = J. Hoskins)

- B** - BP +/- 10%, haemodynamic stability, anticipate stimulation – ETT, pins, local
- R** - Rapid emergence to assess neurology – Remifentanyl, minimal opioid
- A** - Adequate CPP = 60-70 mmHg
- I** - Immobility – REMIFENTANIL  $C_{ET}$  2-4 ng/mL, NDMR (Induction Dose/ 2) per hour
- N** - Neuroprotection – Reduce cerebral metabolism, reduce ICP (Dexamethasone, Mannitol, Strong Salt, ventilation), preserve autoregulation – TIVA>SEVO

## Neuro Evidence

(Source = Brain Trauma Foundation)

- S** - Steroids/ cooling have NO evidence
- M** - Mannitol 0.25-1 g/kg to reduce ICP
- A** - Airway – Traches reduce ICU stays with no change in mortality or VAP rates
- S** - Sedatives reduce ICP
- H** - Hyperventilation reduce ICP in the short-term
- E** - Enoxaparin – Risk vs. benefit after 48 hours
- D** - Drain – EVD if GCS <6 in the first 12 hours
  
- B** - Bolt/ ICP in all patients with GCS <8
- R** - Rescue Craniectomy if ICP >25 mmHg increases GOS 2, reduces GOS 1
- A** - Antiseizure prophylaxis - Phenytoin
- I** - ICP/ BP/ CPP thresholds/ targets
- N** - Nutrition – Reduce mortality. Nasojejunal feeds reduce VAP

## Myaesthesia Post-Operative Ventilation Prediction

- S** - Spirometry – VC <40 mL/kg
- P** - Pyridostigmine - >800 mg/day
- L** - Lung disease
- I** - Peak Inspiratory Pressure <-25cmH<sub>2</sub>O
- T** - Time with disease >6 years

### ASIA Score

**ASIA Score** = American Spinal Injury Association Score

Elements assessed:

- 10 muscle groups on each side
- Pin-prick discrimination at 28 sensory locations

AIS = ASIA Impairment Scale

- Impairment based on anal contraction/ sensation

AIS      Neurology

---

- A**      = Complete Injury
- B**      = Complete motor, incomplete sensory
- C**      = Incomplete motor - >50% muscle groups have <Grade 3 strength
- D**      = Incomplete motor - >50% muscle groups have >Grade 3 strength
- E**      = Normal

### Canadian CT Head Rules

(Source = Lancet 2001)

**If any of the following High Risk Factors, get a CT Head**

- GCS <15
- Depressed/ open skull fracture
- Basilar skull fracture
- >1 vomit
- Age  $\geq$ 65 years

**If no High Risk Factors, get a CT head if:**

- >30 minutes retrograde amnesia
- Dangerous mechanism

**Imaging also recommended if:**

- Blood thinners                      - Focal neurology
- Unstable observations              - Seizures

### TBI BP Goals

(Source = Brain Trauma Foundation 2016)

Age	sBP
<b>15-49 years</b>	>110 mmHg
<b>50-69 years</b>	>100 mmHg
<b>&gt;70 years</b>	>110 mmHg

<b>Adult CPP</b>	60-70 mmHg
<b>Paeds CPP</b>	40-50 mmHg

## Glasgow Outcome Scale

Score 1-5 for outcomes after brain trauma

<u>GOS</u>	<u>Outcome</u>
1	- Death
2	- Persistent vegetative state
3	- Severe disability – Dependent for daily activities
4	- Moderate disability – Independent, but may need equipment
5	- Low disability – Minor neurological and psychological deficits

## TBI Prognosis

(Source = Brain Trauma Foundation)

### **GRAPH**

<b>G</b>	- <b>GCS 3</b>	GOS 1 = 80%	GOS 4/5 = 10%
	- <b>GCS 8</b>	GOS 1 = 10%	GOS 4/5 = 80%
<b>R</b>	- <b>Radiology</b>	Mass effect, midline shift, SAH, Basal Cistern effacement	
<b>A</b>	- <b>Age</b>	Age 11-20 years = 35% mortality. Mortality increases 5-10%/ decade	
<b>P</b>	- <b>Pupils</b>	No standardized approach	
<b>H</b>	- <b>Hypotension</b>	2x increase in GOS 1	

	<u>GOS 1</u>	<u>GOS 4/5</u>
<b>Hypotension</b>	50%	33%
<b>No Hypotension</b>	25%	50%

## Canadian C-Spine Rules

### **Exclusions:**

- GCS <15
- Paralysis
- Unstable observations
- Preexistent spinal disease

### **If any of the following High Risk Factors, get a CT C-Spine**

- Age  $\geq$ 65 years
- Dangerous mechanism – Axial load high speed, bicycle collision, rollover, ejection
- Paraesthesia

### **If no High Risk Factors, clear clinically if a low Risk Factors are present:**

- Simple rear-end crash
- Delayed neck pain
- Sitting in ED
- No C-Spine midline tenderness
- Ambulatory

**Rotate head to 45° to left and right, if unable, get a CT**

**If unable to clear clinically, then get a CT**

## NEXUS C-Spine Rules

**NEXUS** = National emergency Xray Utilisation Study

Canadian C-spine Rules have better sensitivity and Specificity

No Radiology required if there is NO:

- N** - Neurology
- E** - Ethanol
- X** - Extra distracting injuries
- U** - Untoward change in level of consciousness
- S** - Soreness in the midline

## Glasgow Coma Scale

	<u>Eye opening</u>		<u>Voice</u>		<u>Motor</u>
<b>1</b>	Nothing	<b>1</b>	Nothing	<b>1</b>	Nothing
<b>2</b>	To pain	<b>2</b>	Incomprehensible	<b>2</b>	Extension = Decerebrate
<b>3</b>	To voice	<b>3</b>	Inappropriate	<b>3</b>	Flexion = Decorticate
<b>4</b>	Open	<b>4</b>	Confused	<b>4</b>	Withdraws
		<b>5</b>	Orientated	<b>5</b>	Localises
				<b>6</b>	Commands

## Paediatric Glasgow Coma Scale

	<u>Eye opening</u>		<u>Voice</u>		<u>Motor</u>
<b>1</b>	Nothing	<b>1</b>	Nothing	<b>1</b>	Nothing
<b>2</b>	To pain	<b>2</b>	Inconsolable	<b>2</b>	Extension = Decerebrate
<b>3</b>	To voice	<b>3</b>	Moaning	<b>3</b>	Flexion = Decorticate
<b>4</b>	Open	<b>4</b>	Consolable	<b>4</b>	Withdraws to pain
		<b>5</b>	Interactive	<b>5</b>	Withdraws to touch
				<b>6</b>	Purposeful

## 8 - OBESITY

### AHI

**AHI** = Apnea Hypopnea Index, number of Apnea/ Hypopnea events per hour of sleep

	<u>AHI</u>	
<b>Normal</b>	<5	In children AHI >1 is abnormal
<b>Mild OSA</b>	5-15	
<b>Moderate OSA</b>	15-30	
<b>Severe OSA</b>	≥30	

### STOPBANG

S	- Snoring	<u>Risk</u>	<u>Score</u>
T	- Tired/ fatigued/ sleepy	<b>Low</b>	0-2
O	- Observed apneas	<b>Moderate</b>	3-4
P	- Pressure (hypertension)	<b>High</b>	5-8 or 2/4 STOP + B, N or G
B	- BMI >35 kg/m <sup>2</sup>		
A	- Age >50 years		
N	- Neck circumference – Males >43 cm, Females >41cm		
G	- Gender = Male		

### Classes of Obesity

**Obesity** = A state of increased body mass and adiposity with a BMI in excess of >30 kg/m<sup>2</sup>

<u>Class</u>	<u>BMI</u>	<u>Risk</u>
<b>Normal</b>	<25 kg/m <sup>2</sup>	
<b>Overweight</b>	25-30 kg/m <sup>2</sup>	
<b>Class I</b>	30-35 kg/m <sup>2</sup>	Low risk
<b>Class II</b>	35-40 kg/m <sup>2</sup>	Moderate risk
<b>Class III</b>	>40 kg/m <sup>2</sup>	High risk

### James Formulae

Used to calculate Lean Body Mass (LBM)

#### **Males:**

$$\text{LBM} = 1.1 \times \text{Wt}(\text{kg}) - 128 \times (\text{Wt}/\text{Ht})^2$$

#### **Females:**

$$\text{LBM} = 1.07 \times \text{Wt}(\text{kg}) - 148 \times (\text{Wt}/\text{Ht})^2$$

## Dose Adjustments

(Source = BJA 2010)

Propofol	Induction	- <b>LBW</b>
	Maintenance	- <b>TBW</b>
Fentanyl/ Remifentanyl		- <b>LBW</b>
Suxamethonium		- <b>TBW</b>
NDMRs		- <b>IBW</b>

## Obesity Hypoventilation Syndrome

Diagnosis requires:

- **BMI**                    - BMI >30 kg/m<sup>2</sup>
- **ABG**                    - PaCO<sub>2</sub> > 6.0 kPa/ 45 mmHg
- + No other explanation for hypercapnea/ Type 2 Respiratory Failure
  - Drugs                        - Chest wall/ spine disease
  - Medications                - Lung disease
  - Hypothyroidism

## 9 - OBSTETRICS

### Obstetric Sieve

#### Causes if obstetric collapse. Consider:

- Patient factors
- Obstetric factors
- Anaesthetic factors

<b>T</b>	- Thrombus	<b>B</b>	- Baby – Aortocaval compression, eclampsia
<b>H</b>	- Haemorrhage	<b>A</b>	- Anaphylaxis
<b>E</b>	- Embolus – AFE, PE	<b>S</b>	- Sepsis
		<b>I</b>	- Iatrogenic
		<b>C</b>	- Cardiac
		<b>S</b>	- Sugars

### Obstetric Drug Safety

Category	Animal Risk	Human Risk	Overall	Examples
<b>A</b>	No	No	No known adverse effects	Amoxicillin Paracetamol
<b>B</b>	Either Yes Or No	No Unknown	No risks in humans	Augmentin Ondansetron
<b>C</b>	Yes	Unknown	Potential risk	NSAIDs, Sulfonamides, Ciprofloxacin, Trimethoprim
<b>D</b>		Yes	Benefits >Risk	SSRIs, Phenytoin, Valproate, ACEi, Aminoglycosides
<b>X</b>		Yes	Risk >> Benefit	Thalidomide, Isotretinoin

### Intrauterine Fetal Resuscitation

<b>S</b>	- Syntocinon OFF
<b>P</b>	- Position left lateral tilt
<b>O</b>	- Oxygen
<b>I</b>	- IV Crystalloid
<b>L</b>	- Low BP – Give vasopressor
<b>T</b>	- Tocolysis

### PPH Causes

<b>T</b>	- Tone = 70%	<b>T</b>	- Tissue = Placenta
<b>T</b>	- Trauma = Tears	<b>T</b>	- Thrombin = Coagulopathy

## NICE indications for CTG

(Source = NICE)

- M** - Meconium liquor
- O** - Obstetric bleeding
- N** - Neuraxial
- I** - Increased/ decreased fetal Heart Rate
- T** - Temperature = Maternal Fever
- O** - Oxytocin
- R** - Request by mother

## Labour PCA Recipes

	<u>Concentration</u>	<u>Bolus</u>	<u>Lockout</u>	<u>1 hr max</u>
<b>REMIFENTANIL</b>	2mg/ 100mL = 20mcg/ mL	0.5 mcg/kg (10-50 mcg)	2 minutes	900mcg
<b>ALFENTANIL</b>	10mg/ 50mL = 200 mcg/ mL	100mcg (100-200 mcg)	3 minutes	1200mcg

## C-Section Categories

<u>Category</u>	<u>Delivery Time</u>	
<b>CAT I</b>	<30 minutes	Immediate threat to woman/ fetus
<b>CAT II</b>	60-90 minutes	Early Delivery
<b>CAT III</b>	Earlier than planned	Early Delivery
<b>CAT IV</b>	At a planned time	At a time that suits services

## Risk Factors for Preeclampsia

- P** - Parity = Nulliparous, multiparous
- R** - Renal disease
- E** - Endocrine disorders = Thyroid, diabetes
- E** - Egg/ embryo donor
- C** - Chronic hypertension
- L** - Large women = obesity
- A** - Antiphospholipid antibody syndrome
- M** - Maternal age >35 years
- P** - Previous Preeclampsia



## Resuscitative Hysterotomy

**Aim** = Maternal survival, complete by 5 minutes post-arrest

Indications:

- Maternal cardiac arrest
- >4 minutes of CPR
- Gravid Uterus capable of causing aortocaval compression
  - >20/40 pregnant
  - Uterus palpable above level of umbilicus

# 10 - ORTHOPAEDICS

## BCIS

**BCIS** = Bone Cement Implantation Syndrome

	<u>Patient</u>	<u>Surgical</u>
<b>Risk Factors</b>	<ul style="list-style-type: none"> <li>- ASA III/IV</li> <li>- Pulmonary Hypertension</li> <li>- Cardiac Disease</li> <li>- NYHA III/IV</li> <li>- Old age</li> <li>- Osteoporosis</li> </ul>	<ul style="list-style-type: none"> <li>- Long stem prosthesis</li> <li>- Pathological fracture</li> <li>- Uninstrumented canal</li> <li>- Intertrochanteric fracture</li> </ul>

<u>Grade</u>	<u>Saturations</u>	<u>Systolic Blood Pressure</u>
<b>Grade I</b>	<94%	or Drop >20%
<b>Grade II</b>	<88%	or Drop >40%
<b>Grade III</b>	CPR	

## Reasons to delay Hip Fracture Surgery

(source = AAGBI)

<u>Acceptable</u>	<u>Unacceptable</u>
<ul style="list-style-type: none"> <li>- Hb &lt;80 g/L</li> <li>- Reversible coagulopathy</li> <li>- K<sup>+</sup> &lt;2.8 mmol/L or &gt;6.0 mmol/L</li> <li>- Na<sup>+</sup> &lt;120 mmol/L or &gt;150 mmol/L</li> <li>- Chest sepsis</li> <li>- LV Failure</li> <li>- Correctable arrhythmia with HR &gt;120 bpm</li> <li>- Uncontrolled Diabetes</li> <li>- Palliative</li> </ul>	<ul style="list-style-type: none"> <li>- No staff</li> <li>- No facilities</li> <li>- Minor electrolyte abnormalities</li> <li>- Awaiting an Echocardiogram</li> </ul>

# 11 - PAEDIATRICS

## APGAR

		0	1	2
<b>A</b>	- <b>Appearance</b>	Blue	Blue hands/ feet	Pink
<b>P</b>	- <b>Pulse</b>	Absent	<100 bpm	>100 bpm
<b>G</b>	- <b>Grimace</b>	Nil	On stimulation	Normal
<b>A</b>	- <b>Activity</b>	None	Some flexion	Flexion
<b>R</b>	- <b>Respiration</b>	None	Weak	Strong

## Gillick Competence

(Source = Gillick vs. West Norfolk & Wisbech 1985)

A Child's ability to give consent depends on their capacity to make an informed decision and not their age

## McGill Score

Derived from 6 hours+ of overnight oximetry

- Determines**
- Tonsillectomy and Adenoidectomy urgency
  - Post-operative monitoring requirements
  - Appropriateness for day case

Score	Desaturations		Interpretation
	<90%	<85%	
<b>1</b>	1-2	0	<b>Inconclusive</b> A+T if clinical suspicion, day case
<b>2</b>	3+	1-3	<b>Positive</b> Waitlist for A+T, day case
<b>3</b>	3+	4+	<b>High risk positive</b> Urgent A+T, overnight oximetry/ monitoring after

## Cravero/ WATCHA Scales


Measures of Paediatric Emergence Delirium

Others – PAED, FLACC, CHIPP

	<u>Cravero Scale</u>		<u>WATCHA Scale</u>
<b>1</b>	Obtunded	<b>0</b>	Asleep
<b>2</b>	Asleep but responsive	<b>1</b>	Calm
<b>3</b>	Awake and responsive	<b>2</b>	Crying but consolable
<b>4</b>	Crying >3 minutes	<b>3</b>	Crying inconsolably
<b>5</b>	Needs restraint	<b>4</b>	Agitated, thrashin

Child with a Cold

(Source = Curr Op in Anaesth 2012)



Paediatric Fasting

(Source = ANZCA)

<b>Adults</b>	<u>Food</u> 6 hours	<u>COF</u> 2 hours		
<b>Children &gt;6 months</b>	<u>Food</u> 6 hours	<u>Formula/ Milk</u> 6 hours	<u>Breast</u> 6 hours	<u>COF</u> 2 hours
<b>Children &lt;6 months</b>	<u>Formula/ Milk</u> 4 hours	<u>Breast</u> 3 hours	<u>COF</u> 2 hours	

## Paediatric ETT

<b>Neonatal</b>	ETT	=	<u>Gestational Weeks</u> 10
	Depth	=	(kg + 6)cm
<b>Paediatric</b>	Uncuffed	=	<u>Age</u> + 4 4
	Cuffed	=	<u>Age</u> + 3.5 4
	Lip Depth	=	<u>Age</u> + 12 2
	Nose Depth	=	<u>Age</u> + 15 2

## Target Neonatal Saturations

(Source = NZCOR 2016)

Time	Interquartile Range	Target
<b>1 min</b>	60-70%	>60%
<b>2 min</b>	65-85%	>65%
<b>3 min</b>	70-90%	>70%
<b>4 min</b>	75-90%	>75%
<b>5 min</b>	80-90%	>80%
<b>10min</b>	85-90%	>85%

## Paediatric BP/ HR

### **Heart Rate**

Age	Too Slow	Too Fast
<b>&lt;1 year</b>	<100 bpm	>180 bpm
<b>1-4 years</b>	<90 bpm	>160 bpm
<b>5-12 years</b>	<80bpm	>140 bpm
<b>&gt;12 years</b>	<60bpm	>130 bpm

### **Blood Pressure**

Age	Systolic BP
<b>0-3 months</b>	>50 mmHg
<b>4-12 months</b>	>60 mmHg
<b>1-4 years</b>	>70 mmHg
<b>5-12 years</b>	>80 mmHg
<b>&gt;12 years</b>	>90 mmHg

## Paediatric Resuscitation

- W** - Weight = (Age + 4) x2  
**E** - Energy = 4 J/kg  
**T** - Tube – Cuffed = (Age/4) + 3.5, Uncuffed = (Age/4) + 4, Depth = (Age/2) + 12  
**F** - Fluid = 20 mL/kg  
**A** - Adrenaline = 10 mcg/kg, Amiodarone = 5 mg/kg, Atropine = 20 mcg/kg  
**G** - Glucose – D10W 2.5 mL/kg

## Paediatric Anaphylaxis

(Source = ANZCA)

<12 years of age

**DR** - Danger and Response  
Stop procedure, remove trigger

**S** - Send for help and form a team  
Anaphylaxis Box  
Leader and a Reader

**AB** - Airway/ Breathing  
FiO<sub>2</sub> = 100%, ETT early

**C** - Circulation  
Raise legs  
Volume = 20 mL/kg crystalloid

**D** - Drugs  
ADRENALINE

**IM ADRENALINE** Q5 minutes  
If no IV access/ no haemodynamic monitoring  
ADRENALINE 1:1000, Lateral Thigh  
<6 years – 0.15mL = 150 mcg  
6-12 years – 0.3mL = 300mcg

**IV ADRENALINE** Q1-2 minutes  
ADRENALINE 1mg/50ml, 20mcg/mL  
GD II = 0.1 mL/kg = 2 mcg/kg  
GD III = 0.2-0.5 mL/kg = 4-10 mcg/kg  
GD IV = ACLS 10 mcg/kg

**ADRENALINE INFUSION**  
After 3x Adrenaline boluses  
ADRENALINE 1mg/ 50mL  
0.3-6 mL/kg/hr = 0.1-2 mcg/kg/min

### **ONGOING HYPOTENSION**

NORADRENALINE 0.1-2 mcg/kg/min  
VASIPRESSON 1 unit/50ml  
2 mL, then 1-3 mL/ hr

### **ONGOING BRONCHOSPASM**

SALBUTAMOL <6 years - 6 puffs  
>6 years – 12 puffs  
MAGNESIUM 50 mg/kg

## Paediatric Weight

**Weight** = (age+4) x 2

**Age <9 years** Weight = (2x Age) + 9

**Age >9 years** Weight = Age x 3

## Specialist Paediatric Hospitals

- Neonates <28 days
- Ex-prem <37/40 with a post-conceptual age <52 weeks
- History of apneic episodes
- Complex children ASA >3

## Paediatric One-Lung Ventilation

(Source = BJA Ed, SPANZA)

<u>Age</u>	<u>Technique</u>
<b>0-6 months</b>	SLT bronchial intubation
<b>6 months – 2 years</b>	Parallel blocker
<b>2-8 years</b>	Coaxial blocker
<b>8-18 years</b>	DLT 26F

# 12 - PAIN

## Approach to Regional

### **CALM, SOBER, PLANS & ACTIONS**

<b>C</b>	- Consent	<b>P</b>	- Probe = Linear f = 8-15 MHz
<b>A</b>	- Assistant	<b>L</b>	- Local anaesthetic
<b>L</b>	- Lines	<b>A</b>	- Additives
<b>M</b>	- Monitoring	<b>N</b>	- Needle
		<b>S</b>	- Stimulator 0.2 mA
<b>S</b>	- Sedation		
<b>O</b>	- Oxygen	<b>A</b>	- Arrange the room
<b>B</b>	- Block trolley	<b>C</b>	- Clean = 0.5% Chlorhex + 70% EtOH
<b>E</b>	- Emergency drugs	<b>T</b>	- Two person time out
<b>R</b>	- Resuscitation equipment	<b>I</b>	- Image
		<b>O</b>	- Optimise = Depth, gain
		<b>N</b>	- Note relevant structures
		<b>S</b>	- Surround nerve with local anaesthetic

## Bromage Scale

Grade	Criteria	Block
<b>1</b>	Free movement of feet and legs	Nil = 0%
<b>2</b>	Free movement of feet, just able to flex knees	Partial = 33%
<b>3</b>	Unable to flex knees	Almost complete = 66%
<b>4</b>	Unable to move legs	Complete = 100%

## Brachial Plexus

<b>R</b>	- <b>RUGBY</b>	Roots
<b>T</b>	- <b>TEAMS</b>	Trunks
<b>D</b>	- <b>DRINK</b>	Divisions
<b>C</b>	- <b>COLD</b>	Cords
<b>B</b>	- <b>BEERS</b>	Branches

## Analgesic Infusions

For each patient, have plans for:

<b>M</b>	- Monitoring
<b>O</b>	- Ongoing pain
<b>R</b>	- Respiratory depression
<b>P</b>	- Pain team follow-up
<b>H</b>	- Hypotension
<b>I</b>	- Itch
<b>N</b>	- Nausea and vomiting
<b>E</b>	- Emergency management

Institutional Issues:

<b>P</b>	- Protocolised care
<b>U</b>	- Up-to-date education for staff
<b>M</b>	- Management group – GA/QI
<b>P</b>	- Pumps – Cost effectiveness etc

## Tolerance/ Dependence/ Addiction

<b>Tolerance</b>	Acquired hypoactivity to a drug whereby larger doses are required to achieve the same effect
<b>Dependence</b>	Physiological and psychological need for a drug with potential for withdrawal on cessation
<b>Addiction</b>	Use despite harm
<b>Tachyphylaxis</b>	Rapid reduction in drug effectiveness with repeated doses

WHO Definition of dependence =  $\geq 3/6$  of

- A** - Alternative pleasures rejected
- D** - Desire to use
- D** - Detrimental to life
- I** - Inability to control onset/ offset/ levels
- C** - Cessation causes withdrawal
- T** - Tolerance

## Budapest Criteria for CRPS

- CRPS 1** No nerve injury
- CRPS 2** Nerve injury

- C** - Continuing pain disproportionate to inciting event
- R** - Reports 3/4 symptoms
- P** - Presents with 2/4 signs
- S** - Signs and symptoms have no other explanation

## **Signs/ symptoms:**

- Sensory
- Motor/ trophic
- Sudomotor/ oedema
- Vasomotor

## Neuropathic Pain

- Dysaesthesia** Spontaneous or evoked unpleasant, abnormal sensation
- Paraesthesia** Abnormal sensation with no apparent physical cause
- Hyperalgesia** Increased response to a noxious stimulus
- Allodynia** Pain due to a non-noxious stimulus (AKA Hyperaesthesia)



# 13 - PERIOPERATIVE

## ASA

E = Emergency

<b>ASA I</b>	Normal healthy patient
<b>ASA II</b>	Mild systemic disease
<b>ASA III</b>	Severe systemic disease
<b>ASA IV</b>	Severe systemic disease that is a constant threat to life
<b>ASA V</b>	Moribund patient who is not expected to survive without operation
<b>ASA VI</b>	Brain dead organ donor

## Anaerobic Threshold

(Source = Blue Book 2013)

For major abdominal surgery in >60 year old patients

<u>Anaerobic Threshold</u>	<u>Ischaemia on CPEX</u>	<u>Mortality</u>
<b>&gt;11 ml/min/kg</b>	Nil	1%
	Yes	4%
<b>&lt;11 ml/min/kg</b>	Nil	20%
	Yes	40%

## Surgical Urgency

(Source = AHA/ACC 2014)

	<u>Timeframe</u>	<u>Definition</u>
<b>Emergency</b>	<6 hours	Life/ limb threatening, no time to evaluate
<b>Urgent</b>	6-24 hours	Life/ limb threatening, time to evaluate
<b>Time-sensitive</b>	1-6 weeks	Delay of >1-6 weeks will affect outcome (cancer)
<b>Elective</b>	1 year	Delay of 1 year has no effect

## CKD Stages

<u>Stage</u>	<u>Impairment</u>	<u>GFR (ml/min/1.73m<sup>2</sup>)</u>
<b>I</b>	Normal	≥90
<b>II</b>	Mild reduction	60-89
<b>IIIa</b>	Mild-moderate reduction	45-59
<b>IIIb</b>	Moderate-severe reduction	30-44
<b>IV</b>	Severe reduction	15-29
<b>V</b>	Kidney Failure	<15

Child-Pugh Score

(Source = Blue Book 2017)

Surpassed by MELD score

		1	2	3
<b>L</b>	- Low Albumin	>35 g/L	28-35 g/L	<28 g/L
<b>I</b>	- INR	1-4	4-6	>6
<b>V</b>	- Volume/ascites	None	Mild	Severe
<b>E</b>	- Encephalopathy	None	Mild	Severe
<b>R</b>	- Raised Bilirubin	<20	20-30	>30

Child Pugh	Score	Perioperative mortality
<b>A</b>	5-6	10%
<b>B</b>	7-9	30%
<b>C</b>	≥10	80%

MELD Score

(Source = Blue Book 2017)

**MELD** = Model for End-stage Liver Disease, Mayo clinic 2000

$$\text{MELD} = 10 \times (0.96 \times \ln(\text{Creatinine})) + (0.38 \times \ln(\text{Bilirubin})) + (1.1 \times \ln(\text{INR})) + 6.43$$

Derived from 3 parameters:

	MELD	30 day mortality
<b>B</b> - Bilirubin	10	5%
<b>I</b> - INR	20	20%
<b>C</b> - Creatinine	30	40%
	40	60%

*Note: Arrows in the original image indicate that doubling the MELD score (x2) results in a doubling of the 30-day mortality rate.*

Produces a score from 6-40

APFEL/ Eberhart Scores

**APFEL = Adults PONV risk prediction**

Points:	Parameter:	Score:	Risk of PONV:
<b>1</b>	Female	<b>0</b>	10% Low risk
<b>1</b>	Post-operative opioids	<b>1</b>	20% Low risk
<b>1</b>	Previous PONV/ motion sickness	<b>2</b>	40% Intermediate risk
<b>1</b>	Non-smoker	<b>3</b>	60% High risk
		<b>4</b>	80% High risk

**Eberhart = Paediatric PONV risk prediction**

Points:	Parameter:	Score:	Risk of PONV:
<b>1</b>	Age ≥3 years	<b>0</b>	9% Low risk
<b>1</b>	Strabismus surgery	<b>1</b>	10% Low risk
<b>1</b>	Previous PONV/ Family History	<b>2</b>	30% Intermediate risk
<b>1</b>	Duration ≥30 minutes	<b>3</b>	55% High risk
		<b>4</b>	70% High risk

## Insulin Types

Type:	Name:	Additive:	Onset:	Peak:	Duration:
<b>Fast</b>	Novorapid	1x aa changed	10 minutes	1 hour	4 hours
	Adipra	2x aa changed			
	Humalog	Terminal aa changed			
<b>Short</b>	Actrapid	Regular Insulin	30 minutes	2 hours	6 hours
	Humulin	Regular Insulin			
<b>Intermediate</b>	Protophane	Protamine	90 minutes	6 hours	12 hours
<b>Long</b>	Levemir	Fatty acid	90 minutes	-	24 hours
	Lantus				

## Insulin whilst NBM

(Source = Waikato/ AAGBI)

Type:		Day Before:	AM Surgery:	PM Surgery:
<b>Long acting</b>	AM Dose	Usual dose	2/3 dose	2/3 dose
	- Lantus, Levemir PM Dose	2/3 dose	-	-
<b>Intermediate</b>		Usual dose	1/2 Morning	1/2 Morning
- Protophane, Humulin				
<b>Mixed</b>		Usual dose	<b>Either:</b>	1/2 Morning
	- Novomix, mixtard Penmix, Humalog mix		- 1/2 Morning dose - Omit + 0.1 unit/kg Protophane	dose with breakfast
<b>Fast/ Prandial</b>		Usual dose	Omit while NBM	Usual dose with Breakfast
- Adipra, Novomix, Humalog				

## Oral Diabetes Mediations while NBM

(Source = AAGBI)

Class:	Drugs:	<u>Surgery:</u>	
		AM:	PM:
<b>Bisguanides</b>	Metformin	Give/omit	Give/omit
<b>α Glucosidase Inhibitors</b>	Acarbose	Omit	Omit
<b>GLP-1 Analogues</b>	Exenatide	Give	Give
<b>DPP-4 Inhibitors</b>	Sitagliptan, Vildagliptan	Give	Give
<b>Thiazolidinediones</b>	Rosiglitazone, Pioglitazone	Give	Give
<b>Sulfonylureas</b>	Gliclazide, Glipazide	Omit	Omit
<b>Meglitinides</b>	Repaglinide	Omit	Give AM dose

with breakfast

### Frailty and Ageing

**Frailty** A multidimensional syndrome characterized by a loss of homeostatic and physiological reserves that increase vulnerability to adverse events

**Ageing** A progressive reduction in viability with diminished ability to maintain homeostasis from middle life onwards

**Frieds Phenotypes** = 5 Phenotypes of Frailty

	<u>Parameter:</u>	<u>Measurement:</u>
<b>F</b>	<b>Fading</b>	>4.5 kg weight loss
<b>R</b>	<b>Reduced strength</b>	Grip strength in lowest 20%
<b>I</b>	<b>Inactivity</b>	Self-reported
<b>E</b>	<b>Exhaustion</b>	Self-reported
<b>D</b>	<b>Decreased speed</b>	4.5m walk test in lowest 20%

### TIVA Indications

- I** - Intensive care
- T** - Tone of Uterus – GA C-sections
- S** - Short/ day stay
  
- T** - Thoracics – Reduces shunt, increases  $P_aO_2$  in OLV
- I** - Inter/ intrahospital transports
- V** - Vomiting/ PONV prevention
- A** - Anaesthesia for neurosurgery
  
- T** - Trainee teaching
- I** - Individual patient choice
- M** - Malignant hyperthermia
- E** - ENT/ FESS/ Shared airway surgery

### Infection Prevention

#### **SPACE**

- |          |                    |  |   |
|----------|--------------------|--|---|
| <b>S</b> | <b>Surgical</b>    | - Sterility<br>- Reduce tissue trauma        | - Minimise drains/ catheters<br>- Prevent haematomas/ seromas           |
| <b>P</b> | <b>Patient</b>     | - Normoglycemia<br>- Smoking cessation       | - MDRO screening<br>- Pre-operative Chlorhexidine wash                  |
| <b>A</b> | <b>Anaesthetic</b> | - ?Opioids/ steroids<br>- Equipment cleaning | - Asepsis/ CLAB prevention<br>- Hand hygiene                            |
| <b>C</b> | <b>Chemo</b>       | - Antibiotics<br>- Skin prep                 | - WHO timeout confirmation of Abs<br>- Target likely pathogens with Abs |
| <b>E</b> | <b>Environment</b> | - Reduce foot traffic<br>- Temperature       | - Standard precautions<br>- Room ventilation                            |

# 14 - PROFESSIONAL

## Mandatory Reporting

### **MCNZ/ AHPRA notifiable conduct:**

- Practicing whilst intoxicated
- Sexual misconduct
- Impaired
- Significant departure from accepted professional standards

## Graded Assertiveness

<b>P</b>	- <b>Probe</b>	Do you know that...?
<b>A</b>	- <b>Alert</b>	Can we reassess...?
<b>C</b>	- <b>Challenge</b>	Are you sure...?
<b>E</b>	- <b>Emergency</b>	STOP

## SUD Major and Minor signs

(Source= ACECC 2016)

These are indirect signs. Direct signs of SUD is observed misuse = Medical emergency

### **Major:**

- Injection marks/ pills
- IV equipment at home/ in change room
- Increasing sign outs of controlled drugs
- Inconsistent records
- Excessive pain in PACU
- Tremors
- Intoxication
- Bizarre behaviour

### **Minor:**

- Long sleeves
- Blood on clothes
- Absenteeism
- Reduced hygiene
- Poor punctuality
- Frequent job changes
- In Hospital out of hours
- Syringes/ ampules in clothing
- Long toilet breaks
- Mistakes
- Health problems
- Social disruption
- Change in mood
- Working alone
- Refusing breaks

**≥1 major sign = Report**

## Factors that adversely affect decision making

(Source = EMAC)

### **HALT I'M SAFE**

<b>H</b>	- Hungry	<b>S</b>	- Stress
<b>A</b>	- Angry	<b>A</b>	- Alcohol
<b>L</b>	- Late	<b>F</b>	- Fatigue
<b>T</b>	- Tired	<b>E</b>	- Eating
<b>I</b>	- Illness		
<b>M</b>	- Medications		

## Life Problems

Causes = **6 B's**

- |          |                                |          |                                |
|----------|--------------------------------|----------|--------------------------------|
| <b>B</b> | - <b>Babies</b> = Children     | <b>B</b> | - <b>Bugs</b> = Illnesses      |
| <b>B</b> | - <b>Booze</b> = Substance use | <b>B</b> | - <b>Babes</b> = Relationships |
| <b>B</b> | - <b>Banks</b> = Finances      | <b>B</b> | - <b>Blues</b> = Mental health |

## Substance Use Disorder Policies and Interventions

### **PREPARE and STONED**

Policies:

- |          |                                    |  |
|----------|------------------------------------|--|
| <b>P</b> | - <b>Prevention strategies</b>     | Education, controlled drug sign out processes, SIG |
| <b>R</b> | - <b>Recognition</b>               | Education, reporting, audits                       |
| <b>E</b> | - <b>Evidence gathering</b>        | Confidential, welfare SIG                          |
| <b>P</b> | - <b>Planned intervention</b>      |  |
| <b>A</b> | - <b>Access to treatment</b>       | Immediate rehabilitation                           |
| <b>R</b> | - <b>Return to work</b>            | As appropriate                                     |
| <b>E</b> | - <b>Evaluation and monitoring</b> |  |

Interventions:

- S** - **Support return to work**
- T** - **Take time to listen**
- O** - **Outline team roles at outset**
- N** - **Notify person about evidence**
- E** - **Escort at all times**
- D** - **Document everything**

### Return to work process

(Source = ANZCA)

4 stage process based on a learning-needs analysis

Stage:	When:	What:	How:
<b>I</b>	Before/ early	Emergency response CPDs	CICO, ACLS, massive haemorrhage
<b>II</b>	Early	Ability to practice	Level 1 supervision, CPD peer review
<b>III</b>	Variable	Supervision	Audit, logging, MSF, CBDs
<b>IV</b>	End	Completion vs. extension	Supervisors report

### SPIKES Protocol

Protocol for breaking bad news

- |          |                            |                                  |
|----------|----------------------------|----------------------------------|
| <b>S</b> | - <b>Setting</b>           | Location, privacy, uninterrupted |
| <b>P</b> | - <b>Perception</b>        | What is known already?           |
| <b>I</b> | - <b>Invitation</b>        | To give information              |
| <b>K</b> | - <b>Knowledge sharing</b> | Give information                 |
| <b>E</b> | - <b>Empathy</b>           | Emotional response               |
| <b>S</b> | - <b>Summary/ strategy</b> | Where to?                        |

## Open Disclosure

(Source = ANZCA)

An open discussion of adverse events

- Prepare**
- Gather all necessary information
  - Confirm participants
- Perform**
- Introduce roles
  - Offer a sincere, unprompted apology
  - Provide a factual explanation
  - Encourage descriptions of personal experiences
  - Take care of staff - 1° and 2° victims
  - May require several meetings
- Follow up**
- Senior clinician/ management
  - Agree on future care
  - Share outcomes of investigations

Can use **SPIKES** protocol as well

## Bullying Behaviours

(Source = ANZCA)

### **BULLIES**

- B** - Berating, rude, abusive behaviour
- U** - Unreasonable timelines
- L** - Leaving all unpleasant tasks to an individual
- L** - Limiting or withholding essential information
- I** - Intimidating, hostile, threatening behaviours
- E** - Excluding from college activities
- S** - Sarcasm and insults

## Principles of a Complaints Process

(Source = ANZCA)

### **COMPLAIN**

- C** - Confidentiality
- O** - Objectivity
- M** - Malice-free
- P** - Protect against false accusations
- L** - Let each party have a support person
- A** - Allow for independent counselling
- I** - Impartiality
- N** - No victimization of complainants


## ANZCA Roles in Practice

(Source = ANZCA)

### **CCLAMPS**

- C** - Communicator
- C** - Collaborator
- L** - Leader/ manager
- A** - Advocate
- M** - Medical expert
- P** - Professional
- S** - Scholar

## Audit Cycle



## SAC Events


**SAC** = Severity Assessment Code

- SAC 1** Death or permanent severe loss of function
- SAC 2** Permanent major loss of function or temporary severe loss of function
- SAC 3** Permanent moderate loss of function or temporary major loss of function
- SAC 4** Increased level of care or no injury



## HQSC Reporting

HQSC = Health Quality and Safety Commission NZ



## Root Cause Analysis

**RCA** A method of problem solving to identify underlying faulty processes or system errors that led to a harmful event

### **INSPECT**

- I** - **Identify** Identify the event to investigate and gather information
  - Documents, interviews, investigations
- N** - **Nominate** Nominate a team
  - Facilitator, members
- S** - **Sequence** Sequence of events
  - Create a concise timeline
- P** - **Propose** Propose contributing factors for each timeline step
  - Conditions and factors
- E** - **Examine** Examine the root cause
  - Ask 5 “why’s” for each factor
- C** - **Changes** Implement changes for each root cause
  - Immediate = Temporarily, Longterm = Control, eliminate, accept
- T** - **Test** Test the success of changes made
  - Audit, follow up

## QA/ QI

(Source = ANZCA)

**Quality Assurance**

Establish processes to meet accepted standards

**Quality improvement**

Establish processes to achieve better clinical outcomes

### **3 Goals of QA/QI:**

- Improve quality, safety and experience for individual patients
- Improve health and equity for the population
- Achieve best value for available resources

- Autonomy** Individuals have free will. Those with diminished autonomy need protecting
- Beneficence** Research and interventions should aim to maximise benefits
- Non-Malificence** Human subjects should not be harmed or injured
- Justice** Benefits and risks should be distributed fairly. Also encompasses Human Rights and legal obligations

Informed Consent

(Source = Belmont Report 1979)

Informed consent is a direct application of the principles of Autonomy. Competence is assured until proved otherwise

- Information** Knowledge must be shared regarding:
  - Procedure
  - Purpose
  - Alternatives
  - Risks/ benefits
 With opportunity to ask questions and withdraw consent
- Comprehension** The knowledge must be understood
- Free Will** Consent must be voluntary

6 Domains or Health Care Quality

(Source = Institute of Medicine)

**STEEEP**

- S** - Safe
- T** - Timely
- E** - Effective
- E** - Efficient
- E** - Equitable
- P** - Patient-centered

$$\text{Value} = \frac{\text{Quality}}{\text{Cost}}$$

Errors

(Source = BMJ/ ANZCA/ EMAC)

**Active Errors** Unsafe acts which precede an incident

- Slips - Unintended actions
- Sequence** = wrong order
- Mode** = Wrong mode
- Description** = Wrong object
- Lapses - Errors of omission
- Fixation - Coning of attention
- Violations - Intentional errors
- Fumbles - Clumsiness

**Latent Errors** Resident pathogens in a system. These may be dormant and combine with active errors

## Effective Communication

(Source = Blue Book 2017)

### **LAURS**

<b>L</b>	<b>Listen Reflectively</b>	Listen, reflect, don't interrupt, be comfortable with pauses
<b>A</b>	<b>Acceptance</b>	Of beliefs, emotions, experiences, accepting a patient's alternative view/ reality
<b>U</b>	<b>Utilise Patient's Language</b>	Use the same visual/ auditory/ kinaesthetic language. Use concerns/ strengths
<b>R</b>	<b>Reframe</b>	Reframe a negative thought, perception or behaviour in a helpful manner
<b>S</b>	<b>Suggest</b>	Suggestibility increases when anxious. Can be verbal or non-verbal suggestions

## Performance Shaping Factors

(Source = ANZCA)

<b>Individual</b>	Attention, memory, motor skills, training, knowledge
<b>Teams</b>	Leadership, communication, familiarity
<b>Organisation</b>	Staffing, workload, pressure, hours
<b>Resources</b>	Equipment availability
<b>Ergonomics</b>	Size, shape, quality of equipment

## Handovers

(Source = ANZCA)

### Handover for Breaks: **BREAK**

<b>B</b>	<b>Background</b>	Medical history of patient
<b>R</b>	<b>Record</b>	Chart up to date
<b>E</b>	<b>Equipment</b>	Ensure machine/ equipment are working
<b>A</b>	<b>Anaesthetic</b>	Technique, drugs, lines, airway & current state
<b>K</b>	<b>Keep others in the loop</b>	Notify nurses/ tech/ surgeon

### Handover of care: **PISS OFF HOME**

#### P Prepare for the handover

<b>I</b>	<b>Individuals</b>	Who needs to be there?
<b>S</b>	<b>Setting</b>	Where should it occur?
<b>S</b>	<b>Specific paperwork</b>	Documentation ready for handover

#### O Optimise the Environment

<b>F</b>	<b>Facilities</b>	Facilities and equipment to reduce risk for patient/ staff
<b>F</b>	<b>Forewarn</b>	To ensure bed/ staff are available

#### H Handover

<b>O</b>	<b>Overview</b>	Utilise ISOBAR
<b>M</b>	<b>Members</b>	Make sure all relevant people are present
<b>E</b>	<b>Ensure</b>	Ensure there is a leader accepting responsibility

## Culture

(Source = ANZCA)

**UNESCO 1982** The complex of spiritual, intellectual, material and emotional features which define a social group. Culture defines:

- Thoughts
- Identity
- Communication
- Values

**Cultural Competence** Challenges the elements of practice which perpetuate inequity. The attitudes, skills and knowledge to treat people of different cultural backgrounds effectively and respectfully. Improves:

- Patient experience
- Clinical outcomes

Principles of cultural competence

- **Respect** Different world views, different health beliefs
- **Communication** Setting, time, family, interpreter
- **Patient Centered** Care tailored to individual needs, avoid generalisations
- **Partnership** Develop a good therapeutic relationship

## Debriefing after a Critical Incident

### **DEBRIEF**

- D** Debriefing chairs the meeting
- E** Ensure confidentiality
- B** Before starting, identify and introduce all team members present
- R** Relate individual experiences and clarify events
- I** Identify learning points
- E** Ensure confidentiality once more
- F** Follow up/ report/ investigate

# 15 - RESEARCH and STATISTICS

## Clinical Trial Phases

**Efficacy** = Ability to produce a result

**Effectiveness** = Success in producing a result (therapeutic effect)

Phase	n=	Participants	Purpose
<b>0</b>	10	Healthy	Pharmacokinetics
<b>I</b>	20-100	Healthy	Dose ranging, safety, efficacy
<b>II</b>	100-300	Diseased	Safety, efficacy
<b>III</b>	1000-2000	Diseased	Effectiveness, therapeutic effect, safety
<b>IV</b>	Post-marketing surveillance		

## Planning a Study

### **RESEARCH** and **PECOT**

<b>R</b>	Review the literature	<b>P</b>	Population/ sample
<b>E</b>	Establish your aims	<b>E</b>	Exposure
<b>S</b>	Study protocol – Design your protocol = <b>PECOT</b>	<b>C</b>	Control
<b>E</b>	Ethics approval	<b>O</b>	Outcomes
<b>A</b>	Apply your protocol to a Pilot Study	<b>T</b>	Tests/ time
<b>R</b>	Review your protocol and modify it as required		
<b>C</b>	Conduct the study		
<b>H</b>	Hypothesis/ conclude based on your data		

## Levels of Evidence

(Source = NHMRC 1999)



<b>I</b>	Systematic review of RCTs
<b>II</b>	Properly designed RCT
<b>III-1</b>	Pseudorandomised control trials
<b>III-2</b>	Cohort/ case control studies
<b>III-3</b>	Comparative studies
<b>IV</b>	Case series
<b>V</b>	Case reports

## Grades of Recommendation

(Source = NHMRC)

<b>A</b>	Evidence can be trusted
<b>B</b>	Evidence can be trusted in most situations
<b>C</b>	Evidence provides some support, but needs care in its application
<b>D</b>	Body of evidence is weak

Types of Data



Statistical Tests

	<u>2 Groups:</u>		<u>&gt;2 Groups:</u>	
	<u>Paired</u>	<u>Unpaired</u>	<u>Paired</u>	<u>Unpaired</u>
<b>Parametric</b>	- Paired Students T	- Unpaired Students T	- ANOVA	- ANOVA
<b>Non-Parametric</b>	- Nominal - Ordinal – Ratio	- McNemar - Wilcoxon Rank Sum	- Chi <sup>2</sup> - Mann Whitney U	- Cochran Q - Cochran Q - Friednman - Kruskell Wallis

Error

- Error** A reduction in data or measurement accuracy as a result of random or systematic purposes
- Random Error** Non-directional variation in data accuracy resultant from uncontrollable or poorly controlled factors. Reduces with increased sample sizes
- Systematic Error** Bias is the introduction of systematic error. Systematic error occurs with same magnitude and direction. Does not change with sample size

# 16 - RESPIRATORY and THORACICS

ppoFEV<sub>1</sub> = Predicted Post-Operative FEV<sub>1</sub>

The lung has 42 segments

- RUL = 6      - LUL = 10
- RML = 4      - LLL = 10
- RLL = 12

$$\begin{aligned} \text{ppoFEV}_1 &= \text{preopFEV}_1 \times \left(1 - \frac{\% \text{ Lung Removed}}{100}\right) \\ &= \text{preopFEV}_1 \times \left(\frac{42 - \# \text{ Segments Removed}}{42}\right) \end{aligned}$$

<u>ppoFEV<sub>1</sub></u>	<u>Risk</u>
>40%	Low Risk
30-40%	Moderate Risk
<30%	High Risk

Markers of Asthma Control

(Source = National Asthma Education & Prevention)

## ASTHMA

<b>A</b>	<b>Activity</b>	Exercise capacity
<b>S</b>	<b>Salbutamol</b>	Frequency of reliever use
<b>T</b>	<b>Take Steroids</b>	Frequency of Prednisone requirement
<b>H</b>	<b>Has Symptoms</b>	How often?
<b>M</b>	<b>Measurements</b>	FEV <sub>1</sub> / PEF
<b>A</b>	<b>Awakenings</b>	Nocturnal wakings

FACED Score

Severity assessment tool for Bronchiectasis

		<u>0</u>	<u>1</u>	<u>2</u>
<b>F</b>	<b>FEV<sub>1</sub></b>	>50%		<50%
<b>A</b>	<b>Age</b>	<70 years		>70 years
<b>C</b>	<b>Colonisation</b>	Nil	Pseudomonas	
<b>E</b>	<b>Extent</b>	1 lobe	2+ lobes	
<b>D</b>	<b>Dyspnea</b>	MRC 1	MRC 2+	

<u>Score</u>	<u>Severity</u>
<b>0-2</b>	Mild
<b>3-4</b>	Moderate
<b>5-7</b>	Severe

### BODE Index

Severity assessment tool for COPD

		<u>0</u>	<u>1</u>	<u>2</u>	<u>3</u>
<b>B</b>	<b>BMI</b>	>21	<21		
<b>O</b>	<b>Obstruction - FEV<sub>1</sub></b>	>65%	50-65%	35-50%	<35%
<b>D</b>	<b>Dyspnea - MRC</b>	≤1	2	3	4
<b>E</b>	<b>Exercise - 6 Minute Walk</b>	>350m	250-350m	150-250m	<150m

Score                      4 Year Survival

**0-2**                      80%

**3-4**                      70%

**5-6**                      60%

**7-10**                     20%

### CURB 65

(Source = British Thoracic Society)

Points:

1	<b>C</b>	<b>Confusion</b>
1	<b>U</b>	<b>Urea &gt;7 mmol/L</b>
1	<b>R</b>	<b>RR ≥30</b>
1	<b>B</b>	<b>sBP &lt;90 mmHg</b>
1	<b>65</b>	<b>Age &gt;65 years</b>

Score:

0-1	<u>Management:</u>
0-1	Outpatient
2	Inpatient short-stay
3-5	Inpatient +/- ICU

Score:                      30 Day Mortality:

**0**                      <1%

**1**                      3%

**2**                      7%

**3**                      14%

**4**                      28%

**5**                      28%

### MRC Scale

(Source = Medical Research Council)

**MRC Scale** = Medical Research Council Dyspnea Scale

<u>Stage</u>	<u>Dyspnea</u>
<b>I</b>	Dyspnea on strenuous exercise
<b>II</b>	Dyspnea up a slight hill
<b>III</b>	Walks slow, stops after 1 mile
<b>IV</b>	Stops after 100m
<b>V</b>	Dyspnea on dressing



GOLD COPD Classification

(Source = GOLD)

<u>Stage</u>	<u>Severity</u>	<u>FEV<sub>1</sub>/ FVC</u>	<u>FEV<sub>1</sub></u>
<b>I</b>	Mild	<70%	>80%
<b>II</b>	Moderate	<70%	50-80%
<b>III</b>	Severe	<70%	30-50%
<b>IV</b>	Very severe	<70%	<30% <u>OR</u> <50% with chronic respiratory failure

Bronchial Blockers:


<u>ETT Size:</u>	<u>Blocker Size:</u>	Fr = Diameter(in mm) x3
<b>4.5</b>	5.0 Fr	
<b>6.0</b>	7.0 Fr	
<b>7.5</b>	9.0 Fr	

# 17 - TRAUMA


## Burns

### Lund-Browder Chart Calculation of %TBSA Burns

#### Adults:



#### Children:



**Parkland Formula** Formula for fluid resuscitation in burns. Use Hartmans. In children, add 0.9% NaCl+D5W according to Halliday Segar 4-2-1 rule

Total Volume =  $4\text{mL} \times \%TBSA \times \text{Weight}$

**First half** – First 8 hours

**Second half** – Second 16 hours

**Baux Score** Survival Prediction for burns

Baux Score = Age + %TBSA OR Score >120 = 50% Mortality  
 = Age + %TBSA + 17 in inhalational burns

#### Criteria for Intubation

- GCS  $\leq$  8
- Oropharyngeal Oedema
- Combative
- A/B Compromised
- Full thickness neck burn
- Agitated

**Inhalational Burns** Maximal swelling occurs 12-36 hours post-burn

#### Major Signs:

- Hoarse Voice
- Brassy Cough
- Stridor
- Facial/ oral burns/ oedema

#### Minor Signs:

- Singed nasal hairs
- Carbonaceous sputum

### Revised Trauma Score

#### **3 parameters:**

- GCS
- Systolic BP
- Respiratory Rate

$$\text{RTS} = (0.94 \times \text{GCS}) + (0.73 \times \text{sBP}) + (0.29 \times \text{RR})$$

<u>Score</u>	<u>GCS</u>	<u>sBP</u>	<u>RR</u>
<b>4</b>	13-15	>89 mmHg	10-29/ minute
<b>3</b>	9-12	76-89 mmHg	>29/ minute
<b>2</b>	6-8	50-75 mmHg	6-9/ minute
<b>1</b>	4-5	1-49 mmHg	1-5/ minute
<b>0</b>	3	0 mmHg	0

RTS <4 = Refer to Trauma Centre

### Injury Severity Score

(Source = Journal of Trauma 2003)

**Major Trauma** = ISS >15 = 10% mortality

<u>6 Body Regions:</u>	<u>Score</u>	<u>Injury</u>
- Head/ neck	<b>1</b>	Minor
- Face	<b>2</b>	Moderate
- Chest	<b>3</b>	Serious
- Abdomen	<b>4</b>	Severe
- Pelvis/ limbs	<b>5</b>	Critical
- External	<b>6</b>	Untreatable/ lethal

$$\text{ISS} = A^2 + B^2 + C^2$$

**A, B, C** = Scores for 3 most injured regions

Maximum ISS = 75

<u>ISS</u>	<u>% Trauma Induced Coagulopathy</u>
<b>0-14</b>	10%
<b>15-29</b>	20%
<b>30-44</b>	40%
<b>45-59</b>	60%
<b>60-75</b>	80%

### Classes of Shock

<u>Class</u>	<u>Volume lost</u>	<u>Physiology</u>
<b>I</b>	<15%	Normal
<b>II</b>	15-30%	HR 100-120, BP normal or reduced, RR 20-24
<b>III</b>	30-40%	Significantly reduced BP, anxious, altered mental state
<b>IV</b>	>40%	Significantly reduced BP, reduced level of consciousness

## Damage Control Resuscitation

**Indications**    - RBC >10units            - Coagulopathy            - T <35°C  
                      - >90 minutes in OT    - pH <7.2                 - Lactate >5 mmol/L

### **3 Components:**

- 1**        - Permissive Hypotension  
                      - sBP 80-90 mmHg until source control unless TBI/ spinal injury
- 2**        - Damage Control Surgery – Rapid and definitive source control
- 3**        - Prevention of Hypothermia, Acidosis, Hypocalcaemia

### **Damage Control Surgery – 4 Phases:**

- 1**        - Early recognition of course
- 2**        - Salvage operation
- 3**        - ICU for            - Resuscitation  
                                      - Correction of coagulopathy  
                                      - Physiological stabilization
- 4**        - Re-operation at 24-48 hours if stable and responding to treatment

## Carboxyhaemoglobin

<u>HbCO</u>	<u>Clinical Presentation</u>	<u>FiO2</u>	<u>HbCO t<sub>1/2</sub></u>
<b>&gt;10%</b>	Symptomatic	<b>0.21</b>	4 hours
<b>&gt;20%</b>	Consider Hyperbaric Oxygen	<b>1.0</b>	45 minutes
<b>&gt;50%</b>	Coma, death	<b>3ATM 1.0</b>	20 minutes